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Alzheimer’s disease is an incurable chronic neurodegenerative disease that results in severe memory loss and 
cognitive function. It is the third most common cause of death and the most common cause of dementia in the 
developed world. To date, a number of possible causes have been identified, however the primary cause is still 
unknown.  Diagnosis generally does not occur until the later stages, resulting in insufficient treatment to 
reverse any damage. Metabolomic analysis is a relatively new technique that aims to identify all metabolites 
present in a biological sample, which could potentially serve as biomarkers. Biomarkers can be used as a 
diagnostic tool and, more importantly, allow identification of the pathways involved in the pathological 
process.  In current Alzheimer’s disease research, the identification of cerebrospinal fluid (CSF) biomarkers is a 
topic of considerable interest. Attaining CSF is a highly invasive process and for this reason is in limited supply, 
therefore it is important that as much information is attained from initial analysis.  
 
In this study an MS/MS method for metabolites, which have so far been identified in CSF, was developed for 
the Bruker SCION triple quadrupole GC-MS, with the aim of profiling unknown samples from initial analysis.  A 
total of 90 features (81 compounds) were constructed into this method, consisting of their retention times and 
optimal precursor-product ion pairs. A combination of these properties should be unique to each compound, 
providing confidence in identification. Constructing this MS/MS method was completed by conducting a series 
of analyses. Full scan analysis established retention times, and identified the most abundant ions for each 
compound. These ions were analysed using a SIM/scan analysis, which identified possible precursor ions. 
Following this, a product ion scan analysis was achieved to identify the product ions generated from 
dissociation of the precursor ions. Finally, the precursor-product ion pairs were established and analysed using 
a multiple reaction monitoring scan analysis. This MS/MS method was generated from reference standards, 
and therefore the data generated from unknown samples can be confirmed with relatively high confidence. 
This should allow identification of the metabolites which are involved in the disease process, ultimately 
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1.  Introduction   
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD) was first identified in 1906 by Dr. Alois Alzheimer following the death of a patient 
from an unfamiliar mental illness (Hippius and Neundorfer 2003). This illness is now described as a chronic 
neurodegenerative disease due to sustained atrophy of the brain that causes significant decrease in 
neurological functioning (Figure 1.1) (Trushina, Dutta et al. 2013). It is characterised by short-term memory loss 
in addition to gradual loss of cognitive function (Trushina, Dutta et al. 2013). AD is the third most common 
cause of death in developed countries and the most common cause of dementia, accounting for 60-80% of all 
dementia cases in the developed world (González-Domínguez, García-Barrera et al. 2012). It is most prevalent 
in elderly individuals, where approximately 20% of people aged 80 years or over develop AD (González-
Domínguez, García-Barrera et al. 2012). Advances in medicine and medical technology are allowing the 
population to live longer, and therefore the number of Alzheimer’s cases is increasing (Fargo and Bleiler 2014). 
Studies have estimated that by 2025 and 2050 the number of people aged 65 years or older with AD in the USA 
will increase to 7.1 million (40% increase) and 13.8 million respectively (Fargo and Bleiler 2014).  Economically, 
AD has a significant impact on the population. In 2013 Americans contributed 17.7 billion hours of unpaid 
caregiving to AD patients, with an estimated economic value of care of $220.2 billion/year (Fargo and Bleiler 
2014). In 2014, Medicare and Medicaid are expected to pay $150 billion for health care, long-term care and 
hospices for people with AD and other dementias. Significant increases in the number of affected individuals in 
the future will dramatically increase these numbers, drastically impacting the economy and society in general 
(Fargo and Bleiler 2014). 
1.2. Stages of Alzheimer’s disease 
1.2.1. Preclinical Alzheimer’s disease 
The first stage of AD begins approximately 10 to 25 years before the development of symptoms. This stage is 
termed the preclinical stage where the patient is completely unaware that something is pathologically 
abnormal, as no symptoms are apparent at this point. This stage involves the formation of the two common 
recognisable pathological lesions; extracellular amyloid beta (A) plaques and neurofibrillary tangles (NFT) 
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which are found in all AD patients. Currently these lesions are the most important indicators for confirming AD 













Figure 1.1: A) represents a healthy brain (left) compared to an Alzheimer’s brain (right). Note the shrinkage of the gyri in the temporal and 
frontal lobes. B) Represents a position emission tomography scan showing glucose uptake in a healthy brain (left) and an Alzheimer’s brain 
(right). Red and yellow indicate high levels of glucose uptake (Mattson 2004). 
 
Extracellular A plaques are produced when the overexpressed amyloid precursor protein (APP) is subjected to 
abnormal cleavage by the inappropriate enzyme β-secretase (Tamagno, Bardini et al. 2002), which cleaves APP 
at the beginning of the Aβ domain, generating a soluble N-terminal fragment and an amyloidogeneic C-
terminal fragment of 99 residues (Figure 1.2). The C-terminal fragment is further cleaved by γ-secretase to 
produce two possible Aβ fragments; A1-40, which is the most common form, or Aβ1-42, which is more 
potent, and more commonly precipitates to form insoluble plaques (Reddy and Beal 2008, González-
Domínguez, García-Barrera et al. 2012, Galimberti, Ghezzi et al. 2013).  Under normal conditions, APP is 
cleaved by an α-secretase enzyme in the Aβ domain generating the large soluble N-terminal fragment and a 
non-amyloidgenic C-terminal fragment consisting of only 83 amino acid residues. The C-terminal fragment is 
further cleaved by γ-secretase to produce the non-amyloidogenic peptide and APP intracellular domain (Reddy 
and Beal 2008).  
 
 












Figure 1.2: The non-amyloidogenic and amyloidogenic pathways of amyloid-beta production (Reddy and Beal 2008). 
 
Neurofibrillary tangles occur when the naturally occurring tau protein is abnormally hyper-phosphorylated and 
forms insoluble fibrils, which result in tangles inside the neurons (González-Domínguez, García-Barrera et al. 
2012, Galimberti, Ghezzi et al. 2013). The process which causes hyper-phosphorylation of tau is yet to be 
confirmed, however it is thought that the up-regulation of tau kinase(s) or down-regulation of tau 
phosphatase(s) could be the potential reason for this abnormality (Matsuo, Shin et al. 1994). The hyper-
phosphorylation of this protein results in a conformational change which makes it insoluble, thus causing the 
protein to aggregate forming neurofibrillary tangles, additionally it loses its biological activity and becomes 











Figure 1.3: The physiological and pathological roles of the tau protein (Johnson and Stoothoff 2004) 
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1.2.2. Mild Cognitive Impairment  
Mild cognitive impairment (MCI) is the first clinical stage of the disease where symptoms become evident. 
However the extent of the regression is minimal, as the daily activities of patients are not affected. At this stage 
patients begin to experience memory problems, however no personality changes or other problems have been 
reported this early in the disease (Rodgers and National Institute on Aging. 2008). Although this occurs during 
the normal ageing process, MCI patients develop memory decline greater than expected for their age. MCI is 
further categorised into subtypes, amnestic MCI is the subtype that most characterises memory loss and 
approximately 8 out of every 10 who are diagnosed with amnestic MCI will progress to develop Alzheimer’s 









Figure 1.4: A theoretical timeline of brain changes in healthy ageing in comparison to AD (Rodgers and National Institute on Aging. 2008) 
 
1.2.3. Mild dementia due to Alzheimer’s disease 
As the patient’s life progresses so does the disease, the severity of the pathological lesions increases and the 
mass of the brain decreases (Figure 1.5). When a patient advances to this stage the symptoms are readily 
apparent, and therefore is commonly when patients are diagnosed with the disease (Rodgers and National 
Institute on Aging. 2008). The patient may appear relatively healthy, but is essentially struggling to make sense 
of the world as the symptoms begin to severely impact their daily activities; the extent of memory loss 
increases in addition to alterations in other cognitive abilities. These include confusion about the location of 
familiar places, poor judgement resulting in bad decision-making and loss of spontaneity and sense of initiative. 
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Patients at this stage begin to develop personality changes, such as increased anxiety and or/aggression (Mega, 
Cummings et al. 1996, Rodgers and National Institute on Aging. 2008).  
1.2.4. Moderate dementia due to Alzheimer’s disease 
By this stage of the disease the damage has spread to the cerebral cortex, the area of the brain which is 
responsible for language, reasoning, sensory processing and conscious thought (Figure 1.5). When the patient 
reaches this stage of the disease, continuous supervision is required due to unintentional wandering and 
agitation. The symptoms are obvious or even extreme by this point of the disease (Rodgers and National 
Institute on Aging. 2008).  The cognitive ability of the patient is severely affected, in addition to a further 
increase in memory loss and confusion, the ability to concentrate decreases, organising thoughts and thinking 
logically becomes difficult and recognising family and friends becomes a challenge for the patient. They 
struggle to learn new things or are unable to cope with new or unexpected tasks, furthermore difficulty with 
language and problems with reading, writing and working with numbers can become evident (Rodgers and 
National Institute on Aging. 2008). The patient’s mood is notably affected at this stage, in which they can 
endure inappropriate outbursts of anger, agitation, anxiety, tearfulness and restlessness. Repeating statements 
or movement can occur, as well as loss of impulse control. Furthermore the patient may endure hallucinations, 
delusions, suspiciousness, paranoia and irritability (Mega, Cummings et al. 1996, Rodgers and National Institute 
on Aging. 2008).  
1.2.5. Severe dementia due to Alzheimer’s disease  
By this stage of the disease the patient depends entirely on others for care and is generally unable to perform 
any basic task, to the extent of no communication and complete inability to recognise family and friends 
(Rodgers and National Institute on Aging. 2008). The patient has no cognitive ability at this stage and the 
symptoms evident at this period include weight loss, seizures, skin infections, groaning, moaning, grunting, 
increased sleeping, lack of bladder and bowel control. Furthermore patients have difficulty swallowing, which 
most commonly is the primary cause of death, as food and liquid can enter the lungs, which results in 
aspiration pneumonia leading to death (Rodgers and National Institute on Aging. 2008). 
 
 







Figure 1.5: The physical changes that occur in the brain as it progresses from preclinical to severe AD (blue area indicating atrophic 
neurons) (Rodgers and National Institute on Aging. 2008) 
1.3. Types of Alzheimer’s disease  
Worldwide, approximately 36 million people suffer from AD. In 2014, an estimated 5.2 million Americans have 
AD, where 5 million of these sufferers are aged 65 years or older (Fargo and Bleiler 2014). The development of 
AD at the age of 65 years or older is termed late onset/sporadic Alzheimer’s disease and is the most common 
type of AD. However a subset of sufferers develop this disease before the age of 65 years, this is termed early 
onset/ familial Alzheimer’s disease. 
1.3.1. Early onset/familial Alzheimer’s disease  
In rare cases, some patients develop Alzheimer’s disease before the age of 65. This type is characterised as 
early onset AD and occurs in approximately 5-10% of all AD patients. Early onset AD can be entirely inherited 
and occurs in less than 0.1% of all cases (Bekris, Yu et al. 2010). This form of AD is due to mutations in three 
particular genes; amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Harvey, 
Skelton-Robinson et al. 2003).  Amyloid precursor protein gene is located on chromosome 21 and codes for the 
amyloid precursor protein; it contains 19 exons of which exons 16 and 17 encode for the Aβ peptide (Konig, 
Monning et al. 1992). Most of the mutations that have been identified in the APP gene are located near the 
alpha, beta and gamma secretase cleavage sites suggesting altered proteolysis of the peptide as an important 
factor (De Jonghe, Esselens et al. 2001). Substitution mutations that are at or near the beta and gamma 
cleavage sites result in the over-production of both forms of Aβ peptide or specifically increases the production 
of the less common, more potent form of the peptide; Aβ1-42 (De Jonghe, Esselens et al. 2001).  
 
PSEN1 and PSEN2 are 12-exon genes that code for proteins that are involved in the γ-secretase complex (De 
Strooper, Saftig et al. 1998). The mutational outcome of these genes are similar, the only factor that differs is 
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the frequency of mutation. Mutations in the PSEN1 gene are the most common cause of this form of AD, more 
than 180 mutations have been identified, with the majority of these being missense mutations (Cruts, Theuns 
et al. 2012). On the other hand, only 14 mutations have been identified in the PSEN2 gene, and this gene rarely 
causes this form of AD (Scheuner, Eckman et al. 1996). The missense mutations cause amino acid substitutions, 
thus altering protein activity consequently interfering with appropriate cleavage of the APP gene product 
(Scheuner, Eckman et al. 1996, De Strooper, Saftig et al. 1998). These mutations appear to result in a significant 
increase and decrease in A1-40 and A1-42 respectively (Scheuner, Eckman et al. 1996).  
1.3.2. Late onset/sporadic Alzheimer’s disease  
As stated the more common type of AD develops after the age of 65 years old and is termed late 
onset/sporadic Alzheimer’s disease. Although there are multiple internal and external influences which have 
been linked to the progression of sporadic AD, such as hypercholesterolemia, hypertension, atherosclerosis, 
coronary heart disease, obesity, diabetes, and smoking, there is currently no known primary cause of this form 
of AD (Sadovnick, Yee et al. 2005, González-Domínguez, García-Barrera et al. 2012).  However, extensive 
research has increased our knowledge of the disease, which has provided some insight into possible causes 
(Sadovnick, Yee et al. 2005, González-Domínguez, García-Barrera et al. 2012). These include; mitochondrial 
dysfunction, oxidative stress, inflammation and immune mechanisms, amyloid plaques, neurofibrillary tangles 
and genetic factors. 
1.3.2.1. Mitochondrial dysfunction  
The mitochondria are highly regulated and active organelles that maintain cell integrity. Thus any damage to 
the mitochondria, such as mutation or generation of reactive oxygen species (ROS), could result in destructive 
consequences for the cell and eventually lead to cell death (Anandatheerthavarada and Devi 2007, Pieczenik 
and Neustadt 2007). Mitochondrial dysfunction is a process where the activity and integrity of mitochondria 
are significantly compromised (Sullivan and Brown 2005). After many years of research and accumulated 
evidence, the theory that mitochondrial dysfunction is associated with AD is well established (Reddy and Beal 
2008). The specific mechanism by which this occurs is unclear, however multiple studies have identified several 
possibilities that suggest mitochondrial dysfunction as a potential cause of AD. Damaged mitochondria result in 
decreased ATP production, oxidative stress, apoptosis and/or necrosis (Atamna and Frey 2007). Multiple 
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subunits for the complexes of the electron transport chain (ETC) are encoded in mtDNA, and therefore any 
mutation could compromise the structure and functioning of the ETC complexes, resulting in inefficient 
oxidative phosphorylation and respiration (Beal 1995). The cell would be deficient in ATP, which in some 
tissues is extremely deleterious (Schon and Manfredi 2003). In addition to decreased ATP production, a 
deficient ETC can further increase the production and accumulation of ROS (Mecocci, MacGarvey et al. 1993).  
1.3.2.2. Oxidative stress  
Oxidative stress occurs when the mitochondria accumulate excessive amounts of reactive oxygen species (ROS) 
(Beal 1995, Markesbery and Carney 1999). A reactive oxygen species (ROS), also known as a free radical, is an 
unstable molecule that contains one or more unpaired electrons. ROS will react with lipids, proteins and DNA, 
thus damaging the membrane of the mitochondrion and the cell, interfering with enzymes and substrates, 
inhibiting other metabolic pathways and introducing mutations (Mecocci, MacGarvey et al. 1993, Smith, Perry 
et al. 1996, Sayre, Zelasko et al. 1997), which is problematic for the mitochondrion, the cell and the overall 
tissue (Mecocci, MacGarvey et al. 1993, Smith, Perry et al. 1996, Sayre, Zelasko et al. 1997). Studies have now 
proven that ROS increases the accumulation of the pathological lesion Aβ by inducing the inappropriate 
enzyme β-secretase (Tamagno, Bardini et al. 2002), which cleaves APP at the beginning of the Aβ domain, 
generating a soluble N-terminal fragment and an amyloidogeneic C-terminal fragment of 99 residues (Figure 
1.2). The C-terminal fragment is further cleaved by γ-secretase to produce two possible Aβ fragments; A1-40 
or Aβ1-42 (Reddy and Beal 2008). Additionally it is now understood that ROS decreases the efflux of calcium, 
resulting in build-up within the cell. Under normal conditions, calcium enters the cell via a voltage-, 
concentration- or ligand-gated channel and leaves via a sodium/calcium exchanger (NCX), or the plasma 
membrane calcium pump (PMCP) (Figure 1.6). Once inside the cell, calcium enters the mitochondrion via a 
uniporter and exits via a mitochondrial sodium/calcium exchanger. Lipid peroxidation and damage to proteins 
of the cell membrane calcium pumps by ROS results in restriction of the efflux of calcium (Keller, Pang et al. 





















Figure 1.6: Plasma and mitochondrial membrane calcium channels (Syntichaki and Tavernarakis 2003) 
1.3.2.3. Inflammation and immune mechanisms 
The inflammation and immune mechanism hypothesis is closely related to the amyloid-beta (A) hypothesis. It 
has been speculated that A triggers the immune system, thus initiating an inflammatory response. Microglia 
are neuronal macrophages, which act to maintain tissue function and detect any foreign or pathogenic 
materials in the brain by the use of their surface receptors (Figure 1.7). These receptors are termed pattern 
recognition receptors (PRR), which recognise pathogen-associated molecular patterns (PAMPs) that are 
conserved pathogen related ligands and danger-associated molecular patterns (DAMPs) that are host derived 
ligands which occur in the form of mis-folded proteins, aggregated peptides or mis-localised nucleic acids 
(Heneka, Kummer et al. 2014). It is thought that A acts as a DAMP, initiating an inflammatory response. In a 
normal physiological state microglia act to phagocytose A, and it is unclear which mechanism causes microglia 
to switch to an aggressive state when activated by AFigure 1.7) (Wisniewski, Barcikowska et al. 1991). 
However, it is understood that there is a significant overlap between PAMP and DAMP signalling pathways, 
thus microglia may not be able to distinguish between an invading pathogen and a tissue-derived ligand. The 
activation of microglia in a pathological state initiates a pro-inflammatory response resulting in the release of 
potentially neurotoxic substances such as cytokines, chemokines, reactive oxygen and nitrogen species and 
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several proteolytic enzymes, which can ultimately cause degenerative damage to neurons (Figure 1.5) (Heneka, 














Figure 1.7: The beneficial and damaging functions of microglia in the brain (Heneka, Kummer et al. 2014) 
1.3.2.4. Amyloid- βeta  
The accumulation of abnormal APP and A is known to increase the production of highly reactive molecules 
that cause damage to the cell (Turrens and Boveris 1980, Mazunin, Volod'ko et al. 2010). Additionally, A 
contributes to increased calcium influx that ultimately results in apoptosis.  It has recently been observed that 
Aβ accumulates not only in the extracellular space but also in the intracellular space, leading to the suggestion 
that intracellular Aβ may have a significant impact on neuronal degeneration (Oddo, Caccamo et al. 2003). It is 
thought that Aβ is produced within the cell and then transported out, accumulating in the extracellular space 
as amyloid plaques. However a proportion of the amyloid precursor protein remains in the cell and resides in 
cellular organelles such as the mitochondrion and endoplasmic reticulum, interfering with functioning (Oddo, 
Caccamo et al. 2003). Studies have found that APP accumulates in the outer mitochondrial membrane import 
channels, preventing cytoplasmic proteins from entering the mitochondrion (Devi, Prabhu et al. 2006). It has 
been stated that many nuclear genes code for proteins which are essential in maintaining the integrity and 
functioning of the mitochondrion, thus these proteins are required to be transported into the mitochondrion 
using the import channels (Chinnery and Schon 2003, Schon and Manfredi 2003, Maruszak and Zekanowski 
2011). A blockage of these channels results in decreased transportation of cytoplasmic proteins, inhibiting 
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maintenance of the structure and function of the mitochondrion (Devi, Prabhu et al. 2006). It has been found 
that this obstruction prevents import of cytochrome c oxidase subunits, suggesting a reason for a decrease in 
cytochrome oxidase activity (Devi, Prabhu et al. 2006). A decrease in cytochrome oxidase activity would result 
in a defective ETC, contributing to the production of excessive ROS resulting in further mitochondrial 
dysfunction and decreased ATP generation generating a vicious cycle (Turrens and Boveris 1980, Mazunin, 
Volod'ko et al. 2010).  
 
Furthermore, Aβ can directly promote calcium influx through the enhancement of voltage-gated channels and 
inotropic glutamate receptors (Carette, Poulain et al. 1993, Price, Held et al. 1998), the formation of channels 
in the membranes (Kawahara and Kuroda 2000), or by stimulating cell surface receptors that are coupled to 
calcium influx transporters (Mattson 2004)(Figure 1.6). Increased calcium in the cell has a deleterious effect on 
mitochondrial membrane permeability. It is known that increased calcium influences the production of the 
mitochondrial permeability transition pore (mPTP), which is only formed and opened in particular pathological 
states, such as oxidative stress, ischemia, traumatic brain injury and stroke (Figure 1.6) (Crompton, Costi et al. 
1987). It has been suggested that this pore consists of the outer membrane voltage-dependent anion channel 
(VDAC), the inner membrane adenine nucleotide translocase (ANT) and the matrix cyclophilin D (Cyc D) (Zheng, 
Shi et al. 2004, Baines, Kaiser et al. 2005, Pestana, Silva et al. 2009). The formation of mPTP requires the 
translocation of Cyc D to the inner mitochondrial membrane. Calcium is a strong inducer of Cyc D, thus 
increased mitochondrial calcium increases the stimulation of Cyc D, initiating the formation of the mPTP 
(Crompton, Costi et al. 1987). The opening of this pore initiates the apoptotic cascade due to the release of 
apoptotic proteins such as the electron carrier cytochrome c and apoptosis-inducing proteins from the 
mitochondrial matrix. Additionally, calcium effluxes from the mitochondrion and cytoplasmic solutes influx into 
the mitochondrion, leading to mitochondrial swelling, ultimately resulting in mitochondrial membrane rupture 
(Baines, Kaiser et al. 2005, Du and Yan 2010). 
1.3.2.5. Taupathy/ Neurofibrillary tangles 
Taupathy occurs when tau, a naturally occurring protein, is abnormally hyper-phosphorylated (González-
Domínguez, García-Barrera et al. 2012, Galimberti, Ghezzi et al. 2013). Physiologically this protein is defined as 
a microtubule-associated protein, and is involved in the development and stabilisation of microtubules. 
Microtubules are an essential component of the cell due to their involvement in maintaining the cytoskeletal 
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structure of the cell, mitosis, intracellular transport and several other functions (Mandelkow, von Bergen et al. 
2007). The biological activity of the tau protein relies on a balance between phosphorylation and 
dephosphorylation, thus an irregularity in this dynamic can modify the activity of the protein. Hyper-
phosphorylation of the tau protein interferes with the proteins ability to assemble correctly, resulting in 
decreased capacity to interact with other proteins to successfully develop and stabilise microtubules (Figure 
1.3). Additionally this protein loses its ability to degrade in this state and instead they form tangles (Wang, 
Grundke-Iqbal et al. 2007, Metcalfe and Figueiredo-Pereira 2010). Therefore, taupathy induces neuronal death 
due to its inability to stabilise microtubules and build up of neurofibrillary tangles, interfering with the 
structural integrity of the cell, causing instability and ultimately cell death (Pooler, Noble et al. 2014).  
1.3.2.6. Genetic factors  
Genetic variation is not generally considered a major contributor to the development of Alzheimer’s disease, 
however it is believed to signify a major risk factor in AD. The APOE gene encodes a cholesterol carrier that 
plays a major role in Aclearance and has now been identified as a gene that can increase the risk of 
developing late-onset AD (Kamboh 2004). Codons 112 and 158 of this gene can occur in three variants (E2, E3 
and E4) with different levels of risk. E3 is known as the normal allele where Cys occurs at codon 112 and Arg 
occurs at codon 158. However E2 and E4 are abnormal alleles where Arg is replaced with Cys at codon 158 in 
the E2 variant and Cys is replaced with Arg at codon 112 in the E4 variant (Farrer, Cupples et al. 1997, Rihn, 
Berrahmoune et al. 2009). Attaining two copies of the E4 variant results in a 15-fold increase in risk as opposed 
to attaining one copy, which results in a 3-fold increase. Furthermore it has been shown that the E2 variant 
decreases the risk of developing AD (Farrer, Cupples et al. 1997).  
 
1.4. Diagnosis  
The diagnosis of Alzheimer’s disease is a difficult process and is only definitively confirmed following a post-
mortem examination of the brain to identify the two lesions present in AD brains. However, AD can be 
diagnosed with 95% confidence at the later stages of the disease (McKhann, Knopman et al. 2011). Whilst 
diagnosis is important, it does not contribute to treatment. Currently, diagnosing AD based on the patient’s 
symptoms at the MCI stage is virtually impossible as memory and cognitive ability commonly decrease as we 
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age regardless of the patient’s pathological state. Additionally, not all patients who are diagnosed with MCI will 
progress to AD (Rodgers and National Institute on Aging. 2008, Albert, DeKosky et al. 2011). The lack of 
diagnosis in the earlier stages of the disease introduces many difficulties as, when diagnosis is finally made, the 
disease may be too advanced to help reverse the damage. This is currently a subject of considerable study, 
since early diagnosis could potentially prolong the patient’s life or, with the appropriate treatment, reverse any 
damage.  
 
In 1983, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the 
Alzheimer’s Disease and Related Disorders Association (ADRDA) established a group that introduced criteria to 
describe the clinical diagnosis of AD (McKhann, Knopman et al. 2011). Diagnosing AD requires multiple tests to 
consider all possible causes. The first test involves a full review of the patient’s medical history, including 
current and past illnesses, any current medications and family medical history. The second test involves a 
physical examination of the patient, including questions about diet, nutrition and alcohol use, medication 
review, blood pressure, temperature and pulse check, heart and lungs check-up and other procedures to 
evaluate overall health (McKhann, Drachman et al. 1984, McKhann, Knopman et al. 2011). Blood and urine 
samples are collected for laboratory testing in order to eliminate other diseases which may be causing AD 
symptoms such as anaemia, depression, infection, diabetes, kidney disease, liver disease, certain vitamin 
deficiencies, thyroid abnormalities and cardiovascular problems. The third test involves a neurological exam 
using MRI or CT. This exam is performed to determine problems that may indicate neurological disorders other 
than AD, such as signs of a stroke, Parkinson’s disease, brain tumours, cerebral oedema and other illnesses 
which many result in memory and cognitive impairment. Additionally the patient will be tested on their 
reflexes, coordination, muscle tone and strength, eye movement, speech and sensation (McKhann, Drachman 
et al. 1984, McKhann, Knopman et al. 2011). The fourth test is a mental status test, which is used to examine 
memory and cognitive ability. There are two types of mental state exams; mini-mental state exam (MMSE), 
which includes a series of questions which test a variety of everyday mental skills. This test is scored out of 30 
and there are 3 score ranges which can indicate the patient’s pathological status; 20-24, 13-20 and less than 
12, suggesting MCI, moderate dementia and severe dementia respectively. The second exam is termed mini-
cog and involves the completion of two tasks; memorise and a few minutes later repeat the names of three 
common objects, and draw a face of a clock showing all 12 numbers in the correct order and then accurately 
placing a time that was specified by the examiner. Since 1984, updated criteria now include the detection of 
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biological biomarkers, however this test is only performed if the patient meets all other criteria. Although 
research has identified two biomarkers, which are present in this disease, their accuracy is not established 
(McKhann, Drachman et al. 1984, McKhann, Knopman et al. 2011). However, biomarkers are a topic of 
considerable interest in current research, and may be the biological entity that can diagnose AD at the stages 
of the disease where neuronal damage is marginal. 
 
In recent years cerebrospinal fluid (CSF) has been considered a useful fluid in studying the changes that occur in 
AD. CSF is a bio-fluid, which occupies the subarachnoid space and the ventricular system around the brain and 
spine. This fluid acts as a cushion to protect the brain and spine from any injury (Anoop, Singh et al. 2010). 
However, it is proposed that CSF is the most informative fluid that best reflects any changes that occur in the 
brain. CSF has the most contact with the brain and is not separated by a regulated blood brain barrier. 
Therefore any protein or metabolite changes in the brain should be reflected in the CSF, and any pathological 
changes would likely appear in the CSF before any other fluid (Anoop, Singh et al. 2010). It is believed proteins 
or metabolites could serve as biomarkers for AD to potentially identify the initial cause of this disease as well as 
a diagnostic technique. However, although considered an informative fluid, obtaining CSF is a highly invasive 
and painful process and for this reason is in limited supply (Anoop, Singh et al. 2010). 
1.5. Treatment  
Currently there is no drug that is capable of curing Alzheimer’s disease; this gives the patient a life expectancy 
of 7-10 years after the identification of symptoms (Cummings and Cole 2002, Perrin, Fagan et al. 2009). 
However, patients are generally prescribed specific medications to improve symptoms and decrease the 
progression of the disease. There are two classes of drug that are administered to AD patients; cholinesterase 
inhibitors and NMDA receptor antagonists. There are currently three types of cholinesterase inhibitor: 
donepezil, rivastigmine and galantamine, all of which ultimately aim to prevent the breakdown of acetylcholine 
(National Institute for Health and Clinical Excellence (Great Britain) 2011). Acetylcholine (ACh) is a 
neurotransmitter that is synthesised by a particular cell type termed the cholinergic neuron. ACh is synthesised 
in the pre-synaptic cholinergic neuron from choline and acetyl-CoA where choline-acetyl transferase (ChAT) is 
the rate-limiting enzyme for synthesis. The neurotransmitter is stored in vesicles and, when stimulated, 
released into the synapse where it binds to the receptors on the post-synaptic neuron. ACh is then degraded by 
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the enzyme acetylcholine-esterase (AChE) to allow for re-uptake into the pre-synaptic neuron through the 
choline transporter and the high-affinity choline uptake transporter (HACU) (Figure 1.8) (Martorana, Esposito 
et al. 2010). Cholinergic neurons are widely distributed in the nervous system and are understood to play a 
critical role in cerebral cortical development, control of cerebral blood flow, sleep-wake cycle, cognitive 
functions, learning and memory (Schliebs and Arendt 2011). The two main classes of ACh receptors are 
nicotinic and muscarinic. A common finding in AD patients is the reduction of nicotinic receptors in addition to 
the complete loss of cholinergic neurons; this combination results in a severe decrease of acetylcholine 
production and decreased cognitive functioning, learning and memory (Schliebs and Arendt 2011). To 
compensate for this biological change, AD patients are administered inhibitors to acetylcholinesterase. 
Inhibiting this enzyme results in decreased breakdown of ACh, therefore increased levels and duration of 
action of ACh in the synapse (Martorana, Esposito et al. 2010).  
 
The second class of treatment is a N-methyl-D-asapartate (NMDA) receptor antagonist known as memantine 
that aims to block the action of glutamate (National Institute for Health and Clinical Excellence (Great Britain) 
2011). Glutamate is an excitatory neurotransmitter, which binds to NMDA receptors resulting in the influx of 
calcium. Unlike acetylcholine, glutamate is in excess in an AD brain, causing excessive calcium influx into the 
neurons (Jones 2002). As previously stated, increased amounts of calcium can initiate many pathways resulting 
in cell death. Memantine is a non-competitive antagonist, which binds to the NMDA receptor, preventing the 

























Figure 1.8: The process of acetylcholine synthesis, which also illustrates the step that is inhibited by the use of drugs. (Martorana, Esposito 
et al. 2010) 
1.6. Metabolomics  
Although a substantial amount of knowledge has been obtained in relation to Alzheimer’s disease, there are 
still gaps in our understanding, preventing us from regulating, preventing and curing the disease. As stated, the 
primary cause of this disease has still not been confirmed which complicates the situation as an appropriate 
treatment is unable to be developed if the target biological pathways are unknown. In addition, there is 
currently no clinical test to diagnose the disease in the early stages which therefore prevents early treatment 
that could potentially help slow the progression of the disease. Thus an extensive amount of research is still 
required to completely understand the biology of AD. Recently, a new technique termed metabolomics has 
become commonly utilised in AD research. Metabolomics is a rapidly emerging technique, which allows the 
detection of the metabolites in a biological sample. Metabolites are small (<1500 Da) intermediate molecules 
that are produced during metabolism and represents an accurate biochemical state of an organism (Wishart, 
Lewis et al. 2008, Trushina and Mielke 2014). Metabolomics is an informative technique which can be used on 
peripheral tissue, CSF and plasma and has the ability to detect the changes in hundreds of metabolites in one 
sample (Trushina and Mielke 2014). There are two types of metabolomics techniques; untargeted and 
targeted. Targeted metabolomics aims to identify particular metabolites in a sample (targeting many 
metabolites in a single analysis rather than just a few as would be obtained from traditional Clinical Chemistry 
tests) as opposed to untargeted which aims to detect as many metabolites as possible. Both are highly useful 
and can allow the identification and quantification of the metabolites present in a particular disease (Trushina, 
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Dutta et al. 2013). The ultimate goal of metabolomics research is to quickly and accurately identify the 
metabolites that are present in a complex sample with minimal manipulation of the samples (Dehaven, Evans 
et al. 2010).  Alterations in the abundance and occurrence of metabolites in a biological entity generally reflects 
the biological pathways that are involved or affected in a particular disease state, and so can theoretically 
provide knowledge of the pathological process (Trushina and Mielke 2014). Furthermore, studying the 
metabolome in healthy and disease conditions can allow the identification of metabolites as biomarkers (Figure 
1.9). Biomarkers are useful in pathology for early diagnosis, monitoring progression of disease, patient 
selection, monitoring side effects, determining the appropriate treatment of disease and in the development of 
new drugs (Sato, Suzuki et al. 2012, Kaddurah-Daouk, Zhu et al. 2013, Lista, Zetterberg et al. 2014).   
 
One major advantage of metabolomics is the understanding that metabolic pathways are conserved through 
evolution, thus the development of potential drugs can be transferred across species, however specific tests 
and human trials are first required (Trushina and Mielke 2014). Nevertheless, one major disadvantage is the 
diversity of the metabolome with regards to its chemical and physical properties due to the large variation in 
atomic configuration. This introduces complications as no single analytical technology is able to account for 
such variation, and thus several technologies are needed to provide the required information (Dunn, Bailey et 
al. 2005).  The analysis of metabolites in biological samples is achieved by using highly developed analytical 
technologies, most commonly nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS), 
which is coupled to either gas (GC), or liquid chromatography (LC) (Figure 1.10) (Halket, Waterman et al. 2005, 
Trushina and Mielke 2014). Mass spectrometry is the most widely utilised technique for the identification and 
quantification of metabolites, in comparison to NMR this technology has greater sensitivity allowing the 
detection of metabolites that are in low abundance and the identification of a broader range of metabolites 
(Figure 1.10) (Dunn, Bailey et al. 2005). 
 





Figure 1.9: An overview of the complete metabolomics workflow (Ibáñez, Simó et al. 2013) 
 












Figure 1.10: Advantages and disadvantages of 4 common analytical techniques used in metabolomics (Trushina and Mielke 2014) 
1.6.1. Gas Chromatography-Mass Spectrometry (GC-MS) 
Gas chromatography-mass spectrometry (GC-MS) is a commonly utilised technique in metabolomics, 
combining sensitivity and specificity for a wide spectrum of metabolites, and for this reason this technique was 
used in this study (Dunn, Bailey et al. 2005). This technology aims to separate and identify unknown 
compounds within a sample by measuring the intensity of the ions produced.  
 
Gas chromatography constitutes the first part of this technology and works to separate the compounds in a 
sample which are then passed through to the mass spectrometer for analysis. The sample is injected into a 
heated port, which vaporises the sample (Figure 1.11). The sample is then pushed into the column using a 
carrier gas, such as helium. This gas is called the mobile phase (McNair and Miller 2009). A GC column is 
typically a glass or stainless steel tube, which is coated with a suitable non-volatile liquid. The compounds bind 
to the lining of the column and separate based on their vapour pressure. This is termed the stationary phase. 
Compounds that are most volatile spend most of the time in the mobile phase and thus elute from the column 
more quickly (McNair and Miller 2009). The separation of compounds is displayed by a chromatogram which 
plots the relative abundance versus retention time of each compound (Grob and Barry 2004). The retention 
time is defined as the amount of time a compound spends in the mobile phase versus the stationary phase and 
generally represents the volatility of the compound. Retention times are suitable parameters for identifying 
metabolites, however, because times can vary depending on column type and temperature, retention time 
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indices can be used as an alternative comparison to reference compounds. A Kováts index represents the 
retention time of analytes on a particular column compared to the retention seen at the same temperature on 








Figure 1.11: A diagram of a typical gas chromatograph/ mass spectrometer system (Grob and Barry 2004) 
 
A major disadvantage in using GC-MS is the chemical manipulation that is required before analysis. This 
manipulation is a process called derivatisation, which involves the transformation of non-volatile compounds 
to volatile compounds to reduce polarity and increase thermal stability. The derivatisation process involves two 
steps: methoxymation and silylation. Methoxymation causes carbonyl groups to transform into their 
corresponding oximes, which ultimately stabilises the α-keto acids and locks sugars in open-ring conformation. 
Silylation involves the replacement of the active hydrogen’s in functional groups (-OH, -SH, -NH or –COOH) with 
trimethylsilyl (TMS), an alkylsilyl group, ultimately forming a more thermally stable and volatile compound 
(Dettmer, Aronov et al. 2007). Although this process is useful in GC-MS, it can have its limitations. Due to the 
addition of TMS to an active hydrogen group, the mass of the compound increases which can ultimately put 
the compound out of the range of the spectrometer’s upper limit, and so to compensate, a fragment may have 
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1.6.2. Mass spectrometry 
Mass spectrometry occurs in four steps, which ultimately produces a spectrum that displays the relative 
intensity of the fragmented ions versus their mass-charge ratio (m/z).  It should be noted that the majority of 
the ions are produced with only one charge, thus the m/z is equal to the mass of the ion (Grob and Barry 2004). 
The process of mass spectrometry may include the addition of a charge to the original compound, producing a 
molecular ion, or the dissociation of the molecular ion to produce fragmented ions. When compounds initially 
enter the mass spectrometer they undergo a process of electron-impact ionisation (EI) where the compounds 
pass through a beam of high-energy electrons (Figure 1.11). The high impact of these electrons on the 
compound results in the removal of an electron which forms the molecular ion (M
+
), this causes instability in 
the ion that can result in further dissociation to produce fragmented ions (Skoog, Holler et al. 2007). Following 
this, these ions then pass through a mass analyser where they are separated according to their m/z. The final 
step of mass spectrometry involves the detector. The resolved ions travel from the analyser to the ion detector 
(Figure 1.11). When the ions hit the detector plate, it quantifies the number of ions at a particular mass by 
converting the beam of ions into an electrical signal, which is recorded and displayed as a mass spectrum 
(Hoffmann and Stroobant 2007). 
 
There are several mass analysers, which can be coupled to gas chromatography. All GC-MS technologies have 
the ability to run full scan and selective ion monitoring (SIM) scans which provide sufficient metabolite 
identification. A full scan is the most convenient method used in mass spectrometry and generates the full 
spectrum of the sample. This scan involves a mass range scan which covers all predicted compounds, generally 
a mass range of 50 to 600 Da is used (Grob and Barry 2004). The lower range of 50 Da is used to exclude any 
background ions produced from air and carrier gases and the upper range of 600 Da is used because any 
compound which has a molecular mass greater than this is generally too large and cannot be analysed. From 
this scan, retention times and all m/z ratios are obtained. To enhance sensitivity and quantify particular 
compounds, a selective ion monitoring (SIM) method can be used. This technique involves the spectrometer 
scanning specified m/z values for each compound. Commonly, the specified m/z values include the most 
abundant ion, which is termed the base peak, and two or three of the next most abundant m/z values.  Ideally 
the molecular ion should be included if in high abundance (Grob and Barry 2004).  
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Currently the most sensitive GC-MS mass analyser developed is the triple quadrupole. This technology is now 
widely used due to its ability to carry out MS/MS analysis and involves multiple steps of mass spectrometry 
allowing the use of multiple scanning methods, which decrease background noise and can greatly enhance 
sensitivity and specificity for the compounds of interest (Chernushevich, Loboda et al. 2001). The three 
quadrupoles (Q1, Q2 and Q3) each carry out their own task, ultimately increasing metabolite sensitivity and 
allowing for quantitative analysis of a sample.  Q1 is a normal mass filter and selects for the ions. The selected 
ions are then passed into Q2 where they are collided with an inert gas, which causes dissociation. Q3 allows 
analysis of the product ions formed in the collision process (Skoog, Holler et al. 2007).  
 
The use of a triple quadrupole mass analyser allows additional scanning methods to be performed. These can 
include precursor ion scans, product ion scans and multiple reaction monitoring (MRMs) scans which allow for 
greater sensitivity and more confident metabolite identification (Chernushevich, Loboda et al. 2001).  A 
product ion scan is a technique which identifies all of the products ions that are formed from the ionisation of a 
specific precursor ion. This scan is achieved by scanning Q3 while Q1 is set to the mass of a particular precursor 
ion (Figure 1.12). The specific ion chosen is generally the most abundant ion that is identified by a full scan or 
SIM scan. A precursor ion scan is a technique that includes the selection of a product ion to determine the 
precursor ion/s. This technique is achieved by scanning Q1 while Q3 is set to the mass of one of the product 
ions  (Figure 1.12) (Barker, Ando et al. 1999). These techniques are commonly used to identify compounds that 
share common structural properties. Finally, MRM is a technique which allows quantitative analysis with very 
high sensitivity. The reason for high sensitivity is due to the monitoring of one pair of precursor – product ions 
(Figure 1.12). The first quadrupole only transmits a small ion population resulting in minimal background noise. 
The fragment ions produced after collision in Q2 produce distinct signals and chemical noise is randomly 




















Figure 1.12: A diagrammatic representation showing three common scans used by a triple quadrupole mass spectrometer (Domon and 
Aebersold 2006) 
1.6.3. Metabolite identification 
Mass spectrometry generates a chromatographic profile of the biological sample, which contains a significant 
amount of data. The identification of the metabolites that are present in a single sample is achieved through a 
library search. There are two forms of library searching which can be used; an in-house library search which 
uses a database that has been generated from standard compounds, or a commercially available mass spectral 
reference library, such as the NIST (National Institute of Standards and Technology, available at: 
http://chemdata.nist.gov/mass-spc/amdis) database (Figure 1.9). However, a match to a database such as one 
from NIST is not entirely accurate, thus an in-house database is highly recommended for identification.  
 
An in-house mass spectral database is a very useful analysis tool, as it is generated from reference standards on 
the actual instrument(s) being used for the analysis, and thus the data generated from unknown samples can 
be confirmed with relatively high confidence. The database contains retention times, retention indices and the 
m/z values for each standard which allows comparison of samples for easier and accurate identification 
(Halket, Waterman et al. 2005). The m/z values usually compared are the molecular ion, base peak and 
additional highly abundant peaks. The mass of the molecular ion is equivalent to the mass of the compound, 
and the fragmented ions generally represent the compounds chemical structure, thus these ions can assist in 
identifying a compound based on its molecular weight and structure (Grob and Barry 2004).  Nevertheless 
some compounds in the same class can generate very similar mass spectra and thus these properties can’t 
always be used to identify a metabolite.  As previously stated the triple quadrupole mass analyser provides 
Chapter 1   Introduction 
 24 
higher sensitivity and accuracy due to its MS/MS ability (Chernushevich, Loboda et al. 2001). The MS/MS 
method generates precursor and product ion-pairs for the reference standards, thus a metabolite can be easily 
distinguished from a co-eluted metabolite based on this specific knowledge of the reference standard 
(Tsugawa, Tsujimoto et al. 2014). Essentially this mass analyser dramatically decreases background noise 
during quantitation; although there is a loss in overall signal going from Q1 to Q3 there is an even greater 
decrease in noise, which provides an overall increase in sensitivity (Williamson, Zhang et al. 2008). A database 
built on an MS/MS method increases the specificity of the standards; therefore metabolites can be accurately 







Figure 1.13: The workflow of metabolite identification using databases (Patti, Yanes et al. 2012) 
 
 
Following the identification of the significant metabolites, the biological pathways involved can be predicted 
using software including KEGG (Kyoto Encyclopaedia of Genes and Genomes, available at: 
http://www.genome.jp/kegg/) and Vanted (Visualization and Analysis of Networks Containing Experimental 
Data, available at: http://vanted.ipk-gatersleben.de/). Furthermore the software can map biological networks 
displaying any interaction between the predicted pathways.  
1.6.4. Metabolomics of CSF 
Most Alzheimer’s disease metabolomics studies have focused on systemic biofluids to establish any metabolite 
changes in the patients. However, it is predicted that CSF will best reflect the metabolite changes that occur in 
the brain, therefore the use of CSF to detect any metabolite changes in AD is rapidly increasing. However, 
attaining this biofluid is a rather invasive process, meaning it is in limited supply. In many cases, cultured 
neurons or media are used, as it is suspected that the metabolites found in CSF are secreted from neurons, 
based primarily on our understanding of the metabolic pathways that occur within the cells.  
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Using CSF could significantly contribute to the knowledge of the biological changes associated with AD and 
many other neurodegenerative diseases. However for CSF research to advance it is important to first recognise 
all the detectable CSF metabolites. Over the past 50 years multiple approaches have been used to characterise 
the CSF metabolome and to date a significant number have been identified (Wishart, Lewis et al. 2008). In 2006 
David Wishart introduced the human metabolome project and together with his team have now generated the 
Human Metabolome Database (available at: http://www.hmdb.ca/), which consists of all the metabolites that 
have so far been detected in the human organism. To date, the database contains approximately 42,000 
metabolites, which include water and lipid soluble compounds, and also metabolites that were in low 
abundance (Wishart, Jewison et al. 2013).   
 
In 2007 as part of this project, Wishart and his team (2008) performed experimental and literature based 
research to establish a database of CSF metabolites. This research aimed to address four key points; which 
compounds can or have been identified in CSF and the concentration ranges for these metabolites, what 
portion of the CSF metabolome can be routinely identified and/or quantified in CSF using conventional, 
untargeted metabolomics and what analytical methods are best for characterising the CSF metabolome. From 
their research Wishart and his team (2008) have identified 476 metabolites in CSF in which they provided 
concentration ranges for both normal and diseased conditions. It should be noted a concentration range is 
given rather than an exact amount due to the variation that different technologies or laboratories measure.  
They also found that more than one technology is needed to obtain a complete identification of the CSF 
metabolome, which does constitute challenges. However, this universal database specifies the substantial 
knowledge that has already been obtained in relation to CSF. Having this extensive amount of knowledge prior 
to AD CSF research provides a starting point in fully identifying the pathways that are involved in the 
development of this disease. Furthermore this universal database allows for easier data analysis as it provides a 
significant reference for the expected CSF metabolites (Wishart, Lewis et al. 2008).  
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1.7. Hypothesis and aims 
Cerebrospinal fluid is the biofluid that probably best reflects the biochemistry of the brain. The understanding 
that pathologically distinct diseases are characterised by unique physiological pathways suggests that the 
metabolic changes involved will fluctuate depending on how the pathway is altered under pathological 
conditions. This study aims to construct and validate a mass spectral database which can be used to profile 
changes in CSF that may occur with AD or MCI.  
 
This study hypothesised that the up regulation of a particular pathway will result in higher concentrations of 
the metabolites; on the contrary, the down regulation of a pathway will result in lower concentrations of the 
metabolites. Moreover, metabolites, which are detectable in MCI and AD patients but not in healthy patients, 
can indicate that an abnormal pathway that is not usually active in the brain under normal physiological 
conditions, may be involved in the development of the disease.  
 
The principal aims of this study were to: 
 Develop a mass spectral database (full scan, selected ion monitoring, product ion scan and multiple 
reaction monitoring) to profile changes in CSF 
















2. Materials and Methods  
2.1. Chemicals 
The standards used to generate the database were purchased from Sigma-Aldrich (Sydney, Australia). 
Phosphate buffered saline (PBS) (Sigma-Aldrich) used in the cell harvesting process was solubilised to 1 x 
concentration with HPLC water.
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C6-Sorbitol (Sigma-Aldrich) was used as an internal standard for metabolomic 
analysis. The chemicals used for derivatisation were methoxyamine hydrochloride (Sigma-Aldrich) in pyridine 
(Ajax Finechem, Sydney Australia) and N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) (Sigma-Aldrich). 
The n-alkanes C10, C12, C15, C19,C22,C28,C32,C36 (Sigma-Aldrich) were mixed in n-hexane (95%) (LabScan, Adelaide, 
Australia). All experiments in this project used LC-MS-grade methanol and HPLC-grade water (Fisher Scientific, 
Melbourne, Australia).  
2.2. Method development 
Although cerebrospinal fluid (CSF) is a useful biofluid in the study of multiple central nervous system diseases 
and disorders, supply is limited. Therefore it is vital that as much data as possible is captured at initial analysis. 
For this reason an in-house database that comprised of CSF compounds was developed for the Bruker SCION 
triple quadrupole GC-MS (Bruker, Billerica, USA), to enable successful metabolite detection with the minimum 
number of samples. The database is a library that contains retention time, retention index and multiple 
reaction monitoring (MRMs) for each compound, permitting the unknown compounds in a sample to be 
identified when compared to this database. The development of this database involved the generation of full 
scan, selected ion monitoring (SIM), product ion scan and MRM mass spectra for known standards, and using 
this data to determine retention times and fragmented ions.  The combination of these properties should be 
unique to each compound, providing confidence in identification, achieved using the database.  
2.2.1. Defining the database  
The initial step in the development of this database involved mining the Human Metabolome Database (HMDb) 
(available at: http://www.hmdb.ca/) to identify all metabolites that have been detected to date in both normal 
CSF and that from patients with Alzheimer’s disease. This initial database was then further refined based on 




which of the compounds were commercially available as pure standards, and could be obtained within the 
timeframe and budget of the project. Of the 405 compounds identified as potentially present in human CSF, 
104 standards were procured for the initial development of the database. In order to construct the database, a 
specific workflow was followed, as depicted in Figure 2.1. The development of this database involved the initial 
preparation of the standard mixtures followed by 4 different scans to ultimately build a CSF MS/MS metabolite 
database. First a full scan analysis was completed on each mixture to establish retention times, followed by a 
SIM/scan to determine the potential precursor ions for each compound, which were initially identified from full 
scan analysis. The reproducibility of the SIM ions confirmed the precursor ions for each compound. To 
determine the transitions for each compound, a product ion scan analysis was completed at 5 different 
collision energies for each compound to investigate the resulting product ion-precursor ion pairs. Ultimately 
the 5 optimal transitions and their corresponding collision energy were chosen for the final method.  
2.2.2. Preparation of standard mixtures 
The 104 standards were divided into 6 mixtures to facilitate a high-throughput approach to building the 
database (Table 2.1-2.6). A substantial proportion of the standards had previously been used to generate a 
database for the Shimadzu QP2010 single quadrupole GC-MS (accessible at the Separation Science Laboratory, 
Murdoch University), meaning that retention index (RI), retention time (RT) and base peak data was already 
available.  For the remaining standards obtained for this project, where available, RI, RT and base peak was 
obtained from the Human Metabolome Database (available at: http://www.hmdb.ca/). This data was used to 
determine which compounds to include in each mixture. To ensure that each compound could be identified 
during analysis, the compounds in each mixture are required to be approximately 20 retention index units 
apart, preventing co-elution and hence overlapping of compounds in the chromatogram. It was not possible to 
create as few as 6 mixtures with each compound being at least 20 RI apart, therefore the base peak for 
compounds was used to ensure that if they did co-elute, they could be resolved and identified based on the 
mass spectrum. 
 
Approximately 1 mg of each compound was accurately weighed out into separate glass vials and the exact 
weight recorded. 500 μL of methanol was added to each vial before mixing. A further 500 μL of methanol was 




added to the standards which dissolved in the initial volume of methanol, while 500 μL of H2O was added to 
the samples which did not fully dissolve in methanol. As solubility is well known, all sugars were dissolved in 
1000 μL of H2O. Volumes were adjusted based on the exact amount of standard in the vial to attain a final 
concentration of 1 mg/ml.  Standards were aliquoted into the final mixtures to a final concentration of 15 
ng/μL for each compound.  Mixtures were snap-frozen in liquid nitrogen and freeze-dried (FreeZone Plus 
Cascade Benchtop Freeze Dry System, Labconco, Kansas City,USA). Once completely dry, mixtures were stored 

























Figure 2.1: Workflow for generation of GC-MS/MS library, as followed in this project 
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Table 2.1: Compounds included in mixture 1 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 
















L- Arabinose 1663 103 
3,4- Dihyroxybenzenacetic acid 1827 179 




















2- Hydroxyisobutyric acid 1114 131 
 Hypoxanthine 1812 265 





2- Ketobutyric acid 1093 188 
 Kynurenic acid 2068 318 



















































Table 2.2: Compounds included in mixture 2 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 
          Compound Retention Index Base Peak (m/z) 
 Azelaic acid 1801 317 
 Cotinine 1726 98 
 Creatine 1551 115 






















L- Glutamine 1777 156 












 Myo-Inositol 2081 305 















D- Ribose 1678 103 























Table 2.3: Compounds included in mixture 3 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 
          Compound Retention Index Base peak (m/z) 
Cis- Aconitic acid 1753 229 
B- Alanine 1429 174 
























 Homovaniilic acid 1775 209 















 Methylmalonic acid 1219 147 
 Picolinic acid 1332 180 

















 Urea 1249 189 






















Table 2.4: Compounds included in mixture 4 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 





















 Biotin 2476 241 











































 Pyroglutamic acid 1520 156 






































Table 2.5: Compounds included in mixture 5 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 
          Compound Retention Index Base Peak (m/z) 
 Acetylcholine N/A N/A 





 Adipic acid 1500 111 













 Choline N/A N/A 






 Cyancobalamin N/A N/A 
 Glutathione N/A N/A 
 Inosine 2582 217 
 Norephinephrine 2148 174 
 Quinolinic acid 1733 296 
 Zinc N/A N/A 
 
Table 2.6: Compounds included in mixture 6 with retention index and base peak. Compounds were selected as 
they were classified by the Human Metabolome Database as being present in human cerebrospinal fluid. 
Retention indices and base peaks were derived from experimental data previously generated for the Human 
Metabolome Database. Multiple RI indicates multiple derivatisation products. 
 
             Compound Retention Index Base peak (m/z) 





 Arachidonic acid 2383 79 
L- Carnitine N/A N/A 
L- Cystine 2291 218 






 L-Dopa 2093 218 
 Melatonin 2408 232 
3- Methoxytyramine 2041 174 
 Oleic acid 2221 117 








 Taurine 1768 147 
 Thiamine N/A N/A 
 Xanthine N/A N/A 
 
2.2.3. Derivatisation  
Before analysis by GC, non-volatile samples must be derivatised to produce volatile derivatives that can be 
separated by the GC. First, the dried samples were methoximated with 20 μL of methoxyamine hydrochloride 
in pyridine (20 mg/mL) and subjected to a 90-minute agitation at 30°C and 1200 rpm (Eppendorf Thermomixer 




Comfort, Eppendorf South Pacific, Sydney, Australia). The next step involved trimethylsilylation, 40 μL of 
MSTFA was added to the samples followed by agitation in the Thermomixer Comfort for 30 minutes at 37°C 
and 300 rpm. Following this, 5 μL of n-alkanes in hexane was added to the samples, which were then 
transferred to a 2 mL glass vial with 200 μL insert. 
2.2.4. Instrumental analysis 
Samples were analysed using a Bruker 451 GC system coupled to a Bruker SCION triple quadrupole mass 
spectrometer. The front inlet temperature was 230°C in which 1 μL of sample was injected in splitless mode, 
the helium gas flow rate through the Restek 30 m x 0.25 mm x 0.25 μm Rtx-5MS capillary column with a 10 m 
Integra-Guard column (Leco Australia Pty Ltd) was 1 mL/min. The column temperature was held at 70°C for 1 
minute and then was raised at a rate of 1°C/min to 76°C and then at a rate of 5.6°C/min to 325°C and held 
isothermally at 325°C for 10 minutes. The transfer line and ion source were set to 270°C and 200°C 
respectively. The mass spectrometer was operated in multiple scan modes using electron impact ionisation (EI), 
the specific parameters for each scan type are detailed in 2.2.5, 2.2.6, 2.3.1 and 2.3.2. 
2.2.5. Full scan analysis 
Following derivatisation of the 6 mixtures, a full scan analysis was conducted for each mixture. The full scan 
analysis, using the GC method described in 2.2.4 aims to generate a full spectrum of the sample to obtain 
retention times for each compound. Additionally this analysis generates a mass spectrum of each compound 
displaying the fragmented ions. The MS was set to a scan rate of 100 ms and ion masses were scanned in the 
range of mass/charge ratio (m/z) 50 - 650 using a 70 eV electron beam. 
2.2.6. SIM/scan analysis 
The next step to building a MS/MS database involved a SIM/scan analysis, which aims to scan for specific 
fragment ions that were identified from full scan analysis, to establish potential precursor ions for MS/MS. 
From the mass spectrum generated from full scan analysis 2-4 of the most abundant ions were selected to be 
analysed using SIM/scan analysis. Using the GC method described in 2.2.4, the MS method was operated in SIM 




mode. This method was set to have a retention window of 0.5 minutes and a scan time of 50 ms for each 
compound.  
2.3. MS/MS method development 
2.3.1. Product ion scan analysis 
A product ion scan aims to determine the product ions, which develop from specific precursor ions. The 
precursor ions are selected for each compound based on the reproducibility of the SIM ions analysed in 2.2.6, 
using the GC method outlined in 2.2.4. Generation of product ions requires collision induced dissociation (CID), 
and a CID gas (argon) pressure of 1.5 mTorr was used for all experiments. To optimise the collision energy for 
each precursor, 5 different methods were generated using 5 different collision energies, 5, 15, 25, 35 and 45 V, 
and each mixture was analysed with all 5 methods. The MS method was set in product ion scan mode and each 
compound had a retention window that ranged from 0.5 - 1.0 minutes and a scan time of 100 ms. The first ion 
mass was set at m/z 50 and the final ion mass was equal to the mass of the precursor ion. 
2.3.2. MRM scan analysis 
MRM scan analysis aims to scan for particular precursor-product ion pairs to enhance the selectivity for each 
compound. The precursor-product ion transitions were chosen based on the product ions generated in 2.3.1. 
Using the GC method described in 2.2.4, the MS method had a scan time of 100 ms with a retention window of 
0.5 minutes for each compound. Collision energies varied depending on the optimal energy for each precursor 
to product transition, based on the data collected in 2.3.1. The pressure of the CID gas (argon) was set at 1.5 
mTorr. 
2.4. Development of the final method 
2.4.1. Standard preparation  
Although useful, working with mixtures of 10-20 compounds is not representative of a biological sample, which 
may contain compounds that cross-react or co-elute with other compounds. In order to reproduce these 
physiological conditions, a mixture was produced that contained all of the 81 identifiable compounds studied in 




this project. 5 μL of each 1 mg/mL compound was added to one microcentrifuge tube, 10 μL of the resulting 
solution was transferred to a new microcentrifuge tube and 123 μL of methanol was added to create a final 
concentration for each standard of 6 ng/μL. The mixture was snap-frozen in liquid nitrogen and freeze-dried 
overnight. Samples were stored at -80°C until analysis.  
2.4.2. Method optimisation: Phase 1 
Following the MRM scan analysis (2.3.2) a maximum of 5 optimal mass transitions were selected for each 
compound and six methods, one for each mixture were developed, based on the retention time of each 
compound, the optimal mass transitions and their optimised collision energies. Each MS method had a 
retention window of 0.5 minutes and a scan time of 100 ms for each compound. The CID gas (argon) pressure 
was set at 1.5 mTorr and the GC method was as described in 2.2.4. The six final methods were again analysed 
against their corresponding mixtures to confirm the transitions for each compound. The combined mixture (6 
ng/μL) produced in 2.4.1 was analysed using the six methods to detect any cross-reactivity of the compounds 
and ensure no compounds were lost when mixed.  
2.4.3. Method optimisation: Phase 2 
Following the construction of the final methods for each mixture in 2.4.2, a final MS/MS method was generated 
by combining these six methods. Each compound had a retention window of 0.5 minutes and a scan time of 
100 ms, the CID pressure was set at 1.5 mTorr and the GC method was as described in 2.2.4. The six mixtures 
were then analysed using this method to distinguish any artefacts from the actual standards. Finally, the 
combined mixture (6 ng/μL) was analysed using this method to confirm which compounds were reproducible. 
2.5. Determination of limits of detection  
An important aspect in any analysis of a biological sample is the sensitivity of the assay, and how it related to 
the concentration at which compounds of interest are present. A compound may be present in a biological 
sample but at a concentration below the detection limits for this type of instrument. Some compounds may 
show greater reproducibility at lower concentrations. For this reason the combined mixture was used to 
calculate limits of detection, the lowest concentration at which each compound can be detected. Figure 2.2 




illustrates the dilutions used in this analysis. The initial standard preparation described in section 2.4.1 was 
serial diluted (1:100, 1:1000,1:10000,1:100000 and 1:1000000), to develop five final concentrations of 423 
ng/μL, 47 ng/μL, 5.21 ng/μL, 572 pg/μL and 63 pg/μL respectively. The GC method used was as described in 

























Figure 2.2: Dilution series used for limit of detection analysis of standard mixtures. 




2.6.  Validation of database 
To ensure that the method developed in this study could be used in the analysis of biological samples, cultured 
neurons and the media in which they were cultured were used as a substitute for CSF, which is very difficult to 
obtain. This approach allowed both intracellular and extracellular metabolites to be studied.  
2.6.1. Cultured cells  
The human neuroblastoma SH-SY5Y cell line was obtained from the European Collection of Cell Cultures 
(ECACC) and purchased through Sigma Aldrich. Cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) (Sigma-Aldrich) which contained 1% 2 mM L-glutamine, 1% 10,000 U/mL penicillin/streptomycin 
solution and 5% foetal calf serum (Serana, Bunbury, Australia) and incubated at all times at 37°C and 5% CO2 in 
a humidified environment (Thermo Scientific Heraeus Function Line incubator, Scoresby, Australia). 
Conditioned media was collected after each harvest and stored at -80°C until extraction.  
2.6.2. Cell harvesting  
Cells were harvested at passage 25 (approximately 5 x 10
6
 cells). All media in the flask was removed and kept 
for further analysis, the cells were quenched and washed with 5 mL of ice-cold PBS, with caution to avoid 
dislodging cells from the flask surface. PBS was removed from the flask and a further 5 mL of PBS was added 
before the cells were scraped into the PBS using a 25 cm rubber cell scraper. 2.5 mL of the PBS, which 
contained the cells, was collected into a 10 mL tube and immediately put on ice. Cells were snap-frozen in 
liquid nitrogen and freeze-dried overnight, once dry, the samples were stored at -80°C until extraction.   
2.6.3. Extracellular metabolite extraction  
To investigate the extracellular metabolome of the cells, the media in which the cells were cultured was 
extracted using the following protocol. 450 μl of an 8:1 methanol:water extraction fluid was prepared at -20°C, 
the media was mixed well and 50 μl was added to the extraction fluid and vortexed to ensure sufficient mixing. 
Samples were centrifuged for 5 minutes at 16,100 x g at 4°C, following this 100 μl of the supernatant was 
transferred to a fresh 1.5 mL microcentrifuge tube and evaporated using a Concentrator Plus rotary vacuum 




evaporator (Eppendorf South Pacific, NSW Australia). Once the supernatant was almost completely 
evaporated, samples were snap-frozen in liquid nitrogen and freeze-dried overnight. Dried samples were 
stored at -80°C until derivatisation. Both conditioned and fresh media were extracted, with fresh media acting 
as a control.  
2.6.4. Intracellular metabolite extraction 
The extraction of metabolites from neuronal cells was achieved in the following way. Extraction solution 
containing the internal standard 
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C6-Sorbitol (2.6 μg/mL) dissolved in 100% methanol was first prepared. 500 
μl of the extraction solution was added to the sample and then vortexed. Subsequently, the cells were 
homogenised using a tissue lyser (Precellys 24 tissue lyser, Bertin Technologies, Aix-en-Provence France) at 
6500 rpm for 2 x 20 seconds. The samples were centrifuged for 10 minutes at 16,100 x g at 4°C. 100 μl of the 
supernatant was aliquoted into three fresh microcentrifuge tubes and 300 μl of water was added to each tube 
to enable freezing at -80°C. Samples were snap-frozen in liquid nitrogen and freeze-dried overnight. Dried 
samples were stored at -80°C until derivatisation.  
2.6.5. Validation of MS/MS method  
Following extraction of the media and the cells, samples were derivatised using the protocol described in 2.2.3. 
Overall 9 samples were analysed (3 conditioned media samples, 3 clean media samples and 3 cell samples) 
using the SCION triple quadrupole mass spectrometer to validate the MS/MS method described in 2.4.3. The 
GC method used was as described in 2.2.4. 
     





3.1. Defining the database   
The Human Metabolome database (HMDb) (available at: http://www.hmdb.ca/) compiles all the metabolites 
that have so far been identified in the human body. Additionally, this database includes information on 
biofluid, concentration, patient status (normal or abnormal), the condition (disease or disorder), age and sex 
differences for each metabolite.  However, as this study focused on the metabolites found in the CSF of 
Alzheimer’s patients, only a proportion of this database was relevant. The initial step to develop the database 
in this project involved identifying the metabolites which were important for this study. Mining through the 
HMDb resulted in the identification of 405 metabolites in CSF (Table 3.1 and 3.2). Table 3.1 demonstrates the 
metabolites which have so far been identified in the CSF of healthy patients as classified by the HMDb. Table 
3.2 demonstrates the metabolites that have so far been found in the CSF of Alzheimer’s patients, to date only 
two unique metabolites are found in AD CSF (shown in yellow) when compared to the metabolites in Table 3.1. 
It appears that the majority of metabolite changes that occur in Alzheimer’s disease are a change in 
concentration of metabolites, which are also found in healthy patients.  
 
Although 405 compounds were relevant for this project, this initial database was further refined based on the 
compounds which were commercially available as pure standards, primarily due to considerations of 
timeframe and budget. A total of 104 metabolites were obtainable as pure standards and therefore used in the 
development of this database. Table 3.3 illustrates the standards that were used in this project. As previously 
discussed in section 2.2.2, a reasonable proportion of these standards had previously been used to generate a 
database for the Shimadzu QP2010 single quadrupole GC-MS (accessible at the Separation Science Laboratory, 
Murdoch University) meaning that retention index (RI), retention time (RT) and base peak data was already 
available. For the remaining standards, RI, RT and base peak was obtained from the Human Metabolome 
Database where available, (available at: http://www.hmdb.ca/). It should be noted that RI, RT and base peak 
were not available for several compounds (refer to Table 3.3).  
 
This data gathered from the previously generated database was useful when deciding which compounds to 
include in each mixture. As discussed in 1.6.1, the RT is a suitable parameter in identifying a compound in a 




total ion chromatogram, however, the GC column and method used can alter the retention time of a 
compound. Therefore, although the retention time will most likely differ in this project due to the use of a 
different column, the variation is generally marginal, so compound identification can still be attempted using 
the RT data available. Simultaneously, the presence and abundance of the base peak shown in the mass 
spectrum provides another tool for identification of a compound. Additionally, having knowledge of the 
possible trimethylsilyl (TMS) derivative products of each compound can provide information on possible 
fragmentation. Gathering this data prior to analysis provided background GC-MS knowledge of a majority of 


























Table 3.1: Compounds found in the CSF of healthy patients, classified by the Human Metabolome Database as 
being present in human cerebrospinal fluid. 
 
 
















Acetone  L- Arginine  
 
Cortisol 
N-α- Acetyl-L-arginine   Arginine vasopressin 1-8  
 
Cotinine 










 Ascorbic acid 
 
 
Creatinine    
N- Acetylaspartylglutamic acid  L- Asparagine  
 
Cyanocobalamin 
L- Acetylcarnitine  L- Aspartic acid  
 
Cyclic AMP 
 Acetylcholine  
 
Asymmetric dimethylarginine  
 
Cyclic GMP 
N- Acetylneuraminic acid  
 
Azelaic acid  L- Cystathionine 
 Adenine  
 









 Adenosine monophosphate  
 
Beryllium  L- Cystine 










S- Adenosylmethioninamine  
 
Biopterin  12,13- DHOME 
S- Adenosylmethionine  
 
Biotin  9,10- DHOME 
 Adipic acid  
 
Boron  11,12- DiHETrE 
 ADP  
 
Bromide  14,15- DiHETrE 
 Agmatine  
 
Butyric acid  8,9- DiHETrE 
L- Alanine  
 
Butyrylcarnitine       
 
Dihydrobiopterin 










 Alpha-dimorphecolic acid  
 
Caproic acid  3,4- Dihydroxybenzeneacetic acid 
 Alpha-ketoisovaleric acid  
 
Caprylic acid  2,4- Dihydroxybutanoic acid 
 Aluminum  20- Carboxy-leukotriene B4  (S)-3,4- Dihydroxybutyric acid 
2- Aminobenzoic acid  L- Carnitine  3,4- Dihydroxyphenylglycol 






























 Antimony  
 
cis-Aconitic acid  L- Dopa 
L- Arabinose  
 











Table 3.1 continued: Compounds found in the CSF of healthy patients, classified by the Human Metabolome 
Database as being present in human cerebrospinal fluid. 
 
 Dynorphin A   Guanidine  D-2- Hydroxyglutaric acid 




Guanidinosuccinic acid  3- Hydroxyglutaric acid    
11,12- EpETrE  
 






Guanosine diphosphate  8- Hydroxyguanosine 
 
Epinephrine     
 
Guanosine triphosphate  5- Hydroxyindoleacetic acid 





11(R)- HETE  (S)-3- Hydroxyisobutyric acid 
9,10- Epoxyoctadecenoic acid  12- HETE  3- Hydroxyisovaleric acid 
 
Erythritol  15(S)- HETE  4- Hydroxynonenal 
 
Erythronic acid  5- HETE  13S- hydroxyoctadecadienoic acid 
 
Estradiol  8- HETE  3- Hydroxyphenylacetic acid 
 
Ethanolamine  9- HETE  p- Hydroxyphenylacetic acid 
 












Folic acid  
 
Histamine  5- Hydroxytryptophol 
 
Formic acid  L- Histidine  3- Hydroxyvaleric acid 







































Gamma-Glutamyl Glutamine  
 
Hydrogen carbonate  
 
Isobutyric acid 
D- Glucose  2- Hydroxy-3-methylbutyric acid  
 
Isocitric acid 
L- Glutamic acid  5- Hydroxy-L-tryptophan  L- Isoleucine 
L- Glutamine  20- Hydroxy-leukotriene B4  
 
Isopropyl alcohol 
L-α- glutamyl-L-Lysine  (R)-3- Hydroxybutyric acid  8- Isoprostane 
 
Glutaric acid  2- Hydroxybutyric acid  
 
Isovaleric acid   
 
Glutathione  3- Hydroxybutyric acid  15- KETE 
 
Glyceric acid  4- Hydroxybutyric acid  6- Keto-prostaglandin F1a 
 
Glycerol  24- Hydroxycholesterol  2- Ketobutyric acid 
 
Glycerophosphocholine  27- Hydroxycholesterol  7- Ketocholesterol 
 




















Table 3.1 continued: Compounds found in the CSF of healthy patients, classified by the Human Metabolome 
Database as being present in human cerebrospinal fluid. 
 
 
Kyotorphin  Pi- Methylimidazoleacetic acid  L- Phenylalanine 
L- Lactic acid  N(6)- Methyllysine  1- Phenylethylamine 
 
Lead   Methylmalonic acid  O- Phosphoethanolamine 
L- Leucine  (R)-N- Methylsalsolinol   Phosphorus 
 
Leukotriene B4  (S)-N- Methylsalsolinol   Phosphorylcholine 
 
Leukotriene C4  5- Methyltetrahydrofolic acid       Phosphoserine 
 
Linoleic acid   Molybdenum   Picolinic acid 
 
Lithium   Myoinositol   Pipecolic acid 
L- Lysine   Myristic acid   Platinum 
 
LysoPC(18:0)   Neopterin     Potassium 
 
LysoPC(20:4(5Z,8Z,11Z,14Z))   Neuraminic acid   Pregnenolone 
 
LysoPC(20:4(8Z,11Z,14Z,17Z)






LysoPC(P-18:0)   Nicotinic acid  L- Proline 
 
Magnesium   Nitrate   Prolylhydroxyproline 
L- Malic acid   Nitric oxide   Propanal 
 
Malic acid   Nitrite   Propionic acid 
 
Malondialdehyde  S- Nitrosoglutathione   Propionylcarnitine 
 
Manganese  3- Nitrotyrosine   Propylene glycol 
 
Mannitol   Norepinephrine   Prostaglandin B2 
D- Mannose   Normetanephrine   Prostaglandin E2 
 
Melatonin   Oleic acid   Prostaglandin F2a 
 
Mercury   Ornithine   Putrescine 
 
Metanephrine   Oxalacetic acid   Pyridoxal 5'-phosphate 
 
Methanol   Oxidized glutathione   Pyroglutamic acid 





 Oxoglutaric acid 
 
 Quinolinic acid 
3- Methoxytyramine   Oxytocin   QYNAD 
3- Methoxytyrosine   Palladium      Ribitol 
3- Methyl-2-oxovaleric acid   Palmitic acid   Riboflavin 
2- Methylcitric acid   Palmitoleic acid  D- Ribose 
 
Methylcobalamin   Palmitoylethanolamide   Rubidium 
 
Methylguanidine   Pantothenic acid   Ruthenium 
1- Methylhistamine   Parathion  (R)- Salsolinol 
1- Methylhistidine   Pentosidine   Sapropterin 
3- Methylhistidine   Peroxynitrite   Scyllitol 
 








Table 3.1 continued: Compounds found in the CSF of healthy patients, classified by the Human Metabolome 
Database as being present in human cerebrospinal fluid. 
 
 Sepiapterin   Spermine   Triphosphate 
D- Serine   Stearic acid  L- Tryptophan 
L- Serine   Strontium     Tuberculostearic acid 
 Serotonin   Suberic acid   Tungsten 
 Silicon   Substance P  L- Tyrosine 
 Silver   Succinic acid   Uracil 
 SM(d18:0/14:1(9Z)(OH))   Succinic acid semialdehyde   Urea 
 SM(d18:0/16:1(9Z)(OH))  3- Sulfinoalanine   Ureidoisobutyric acid 
 SM(d18:0/16:1(9Z))   Tantalum   Ureidopropionic acid 
 SM(d18:0/20:2(11Z,14Z))   Taurine   Uric acid 








 SM(d18:0/24:1(15Z)(OH))   Thiamine monophosphate   Vanadium 
 SM(d18:0/26:1(17Z))   Thiamine pyrophosphate   Vanylglycol 
 SM(d18:1/16:0)   Thiocyanate   Vasopressin 
 SM(d18:1/18:0)  D- Threitol   Water 
 SM(d18:1/18:1(11Z))  L- Threo-2-pentulose   Xanthine 
 SM(d18:1/18:1(9Z))  L- Threonine   9- xoODE 
 SM(d18:1/24:0)   Thromboxane  D- Xylitol 
 SM(d18:1/24:1(15Z))   Thymine  D- Xylulose 
 SM(d18:1/26:0)   Tin       Yttrium     













































Table 3.2: Compounds found in the CSF of Alzheimer’s patients, classified by the Human Metabolome Database 
as being present in human cerebrospinal fluid.  
 
 
Acetylcholine   8- Hydroxyguanine 
S- Adenosylhomocysteine  8- Hydroxyguanosine 
S- Adenosylmethioninamine  4- Hydroxynonenal 
1,5- Anhydrosorbitol  Myo- Inositiol 
L- Arabitol  L- Isoleucine 
L- Arginine  L- Leucine 
L- Asparagine  L- Lysine 
 
Choline   Manganese 
 
Citrulline   Mannitol 
 
Copper  1- Methylhistamine 
L- Cystine  1- Methylhistidine 
3,4- Dihydroxybenzeneacetic acid  3- Methylhistidine 
 Dopamine   Methylmalonic acid 
 Dynorphin A   Pentosidine 
 Fe2+  L- Phenylalanine 
 Folic acid   Phosphorylcholine 
 Fumaric acid  L- Proline   
 Galactitol   Prolylhydroxyproline 
D- Glucose   Ribitol 
L- Glutamine   Sorbitol 
 
Glycerophosphocholine   Substance P 
 
Glycine   Succinic acid 
 
Glycylproline   Thiamine monophosphate 
L- Histidine   Thiamine pyrophosphate 
 
Homocysteine  L- Tryptophan 
4- Hydroxy-L-proline  L- Tyrosine 
24- Hydroxycholesterol  L- Valine 
27- Hydroxycholesterol   Zinc (II) ion 




Table 3.3: List of commercially available metabolite standards included in the mixtures used to build the 
database. The number of TMS derivatives, retention time, retention index and base peak (m/z) were derived 
from experimental data previously generated or the Human Metabolome Database. 
 
     Compound 









1 27.582 1761 181 
2 25.079 1636 206 
 Acetylcholine N/A N/A N/A N/A 
Cis- Aconitic acid 3 27.408 1753 229 
 Adenine 
2 29.712 1868 264 
2 29.755 1869 264 
 Adenosine 
4 41.506 2642 230 
X 40.953 2603 230 
 Adenosine Monophosphate 
4 N/A 3051 169 
5 N/A 3066 169 
 Adipic acid 2 N/A 1500 111 
 Agmatine 3 N/A 1734 174 
B- Alanine 3 20.575 1429 174 
L- Alanine 
2 12.108 1085 116 





3 N/A 2068 100 
4 N/A 1876 331 
5 N/A 1897 188 
L-α- Aminobutyric acid 
2 N/A 1160 130 
3 N/A 1422 202 
L- Arabinose 4 25.622 1663 103 
 Arachidonic acid 1 N/A 2383 79 
L- Arginine 
2 N/A 1742 70 





2 31.004 1941 332 
X 29.198 1844 173 









2 N/A 1501 100 
3 N/A 1666 116 
4 N/A 1728 188 
4 N/A 1621 188 
4 N/A 1861 188 
X N/A 1557 218 
X N/A 1581 218 
 Azelaic acid 2 28.35 1801 317 
 Biotin 3 39.274 2476 241 
L- Carnitine N/A N/A N/A N/A 
 Cholesterol 1 47.919 3157 43 
 Choline N/A N/A N/A N/A 
 Citric acid 4 28.687 1817 273 
 Citrulline 3 N/A 2105 70 
 Cortisol 
X 49.11 3269 103 
X 49.162 3274 103 
 Cotinine N/A 26.861 1726 98 
 Creatine X 23.39 1551 115 
 Creatinine 
2 N/A 1532 99 
3 N/A 1533 115 
 Cyancobalamin N/A N/A N/A N/A 
L- Cystine 4 N/A 2291 218 
 Cytidine 3 43.504 2647 217 
3,4- Dihydroxybenzeneacetic acid 3 28.9 1827 179 












Table 3.3 continued: List of commercially available metabolite standards included in the mixtures used to build 
the database. The number of TMS derivatives, retention time, retention index and base peak (m/z) were 
derived from experimental data previously generated or the Human Metabolome Database. 
 
        Compound 








 Dopamine 4 33.219 2074 174 
 Epinephrine 
3 29.195 1845 355 
4 31.237 1956 116 
 Ethanolamine 
2 10.027 1000 102 
3 16.597 1266 174 
 Folic acid N/A N/A N/A N/A 
D- Fructose 
5 29.594 1862 217 
5 29.776 1871 217 
 Fumaric acid 2 18.828 1357 245 
 GABA 
3 22.899 1526 174 







5 30.243 1895 204 
5 29.938 1880 319 
5 29.982 1880 319 
D- Glucose 
5 30.048 1885 319 
5 30.437 1902 319 
L- Glutamic acid 
2 22.703 1519 156 
2 22.753 1519 156 
L- Glutamine 3 27.887 1777 156 
 Glutathione N/A N/A N/A N/A 
 Glyceric acid 3 N/A 1319 189 
 Glycerol 3 16.831 1275 205 
 Glycine 
X 12.723 1110 102 
X 17.63 1308 174 
L- Histidine 
3 N/A 1914 154 
4 N/A 2150 100 
 Homocysteine 
N/A 18.162 1330 90 
3 25.68 1668 234 







2 21.647 1472 158 
3 22.763 1522 230 







2 13.861 1157 117 
X 24.212 1594 143 
X 24.317 1599 143 
2- Hydroxyisobutyric acid  2 12.973 1114 131 





1 30.691 1924 130 
1 30.716 1924 130 
2 31.369 1963 202 
2 31.393 1963 202 
 Inosine 4 N/A 2582 217 





4 28.698 1819 273 
4 28.722 1819 73 
4 28.84 1825 273 
4 28.865 1825 273 
L- Isoleucine 2 17.321 1295 158 
2- Ketobutyric acid 1 12.317 1093 188 





2 34.725 2164 192 














Table 3.3 continued: List of commercially available metabolite standards included in the mixtures used to build 
the database. The number of TMS derivatives, retention time, retention index and base peak (m/z) were 
derived from experimental data previously generated or the Human Metabolome Database. 
 
    Compound 








L- Lactic acid 
1 19.678 1392 117 







1 13.852 1155 86 
1 13.935 1159 86 
2 16.775 1274 158 
2 16.758 1274 158 
3 22.211 1495 230 
X 22.197 1495 230 





3 26.539 1712 84 
4 30.535 1915 174 
X 29.323 1852 174 
 Mannitol 
6 30.607 1915 319 
6 30.723 1922 319 
D- Mannose 
5 29.857 1875 319 
5 30.12 1889 319 







1 20.272 1416 104 
2 22.637 1515 176 
X 27.517 1761 248 
 Methoxytyramine 3 N/A 2041 174 
 Methylmalonic acid 2 15.402 1219 147 
 Nicotinic acid 1 17.482 1303 180 
 Norepinephrine 5 N/A 2148 174 
 Oleic acid 1 N/A 2221 117 
 Ornithine 
3 27.456 1750 174 
4 28.65 1815 142 







1 23.373 1550 120 
2 24.971 1630 218 
3 29.773 1871 264 
 Picolinic acid 1 18.232 1332 180 
 Pregnenolone 1 44.19 2841 386 
 Progesterone 
2 45.528 2955 372 







1 14.287 1173 70 
2 17.43 1300 142 





4 27.1 1739 174 
4 27.13 1738 174 
X 18.545 1347 174 




2 27.025 1733 296 
 Pyroglutamic acid 2 22.765 1520 156 
 Ribitol 
5 26.794 1724 217 
5 26.833 1724 217 
D- Ribose 4 25.918 1678 103 
 Scyllitol 6 32.315 2020 318 
L- Serine X 23.768 1570 114 
 Sorbitol 
6 30.603 1915 319 





4 N/A 2193 174 
5 N/A 2251 144 











Table 3.3 continued: List of commercially available metabolite standards included in the mixtures used to build 
the database. The number of TMS derivatives, retention time, retention index and base peak (m/z) were 








      Compound 









6 35.147 2190 174 
6 41.781 2663 174 
 Succinic acid 
2 17.925 1321 147 
2 17.956 1321 147 
 Taurine 3 N/A 1768 147 
 Thiamine N/A N/A N/A N/A 
L- Threonine 
2 17.375 1298 117 
3 19.585 1387 218 







1 34.854 2172 130 
2 35.2 2192 218 
2 35.364 2202 202 







2 29.963 1885 179 
2 30.183 1892 179 
3 30.876 1934 218 
 Urea 2 16.325 1249 189 
 Uric acid 
4 33.611 2099 441 
4 33.627 2099 441 
L- Valine 
1 12.014 1085 72 
2 15.276 1214 144 
 Xanthine N/A N/A N/A N/A 
 Zinc N/A N/A N/A N/A 




3.2. Full scan analysis 
A full scan analysis generates a full mass spectrum of the compounds that exist within a sample. Ultimately, 
this analysis profiles all compounds that are GC amendable, and the time at which they elute from the column. 
The elution time, known, as the retention time is essential data required to build an MS/MS method. Although 
the retention times will differ between brands of columns (and therefore different column chemistry), the 
variation with columns of the same or similar phase will be minimal, and thus the retention times in Table 3.3 
could be used as a guide to estimate the time at which a particular compound would elute. To confirm the 
identification of a compound, the base peak assigned to the compound (Table 3.3) was compared to the base 
peak on the mass spectrum generated. If the retention time was within a narrow range of the expected 
retention time, and the base peak was an exact match, the compound was considered as identified.  By using 
the data in Table 3.3, a total of 81 compounds were identified from the six full scan spectra (Figure 3.1-3.6), 
each scan representing the compounds in their corresponding mixture. However indoleacetic acid, L-
kynurenine, D-mannose, D-fructose, D-galactose, L-proline and D-glucose each eluted at two different 
retention times, and 3-hydroxybutyric acid eluted at three different retention times, bringing the overall total 
to 90 features.  
 
As specified, a full scan spectrum aims to identify the reproducible compounds in a sample and define a 
retention time for each compound. A full scan analysis is also used to choose the most abundant fragment ions 
that are potential precursor ions for building MS/MS transitions. Fragment ions are characterized based on 
abundance, where the most abundant ion, known as the base peak, is depicted as the quantifier ion, followed 
by the next 2-3 most abundant ions that are termed qualifier ions. These are characterised in order as qualifier 
1, 2 or 3 as the abundance decreases.  
 
When observed, the molecular ion was chosen as a SIM ion. For compounds that contained several abundant 
ions, ions with a larger m/z were chosen over ions with a small m/z, and where possible, selected SIM ions 
were greater than m/z 100. Ions m/z 73 and 147 were abundant in almost every mass spectrum generated; and 
therefore would not distinguish two closely related compounds. For this reason these ions were generally not 
selected as SIM ions. However as previously generated data (Table 3.3) indicated that m/z 147 was the base 




peak for both succinic acid and methylmalonic acid, this was assigned as a SIM ion for these compounds. Every 
compound was assigned at least three SIM ions, excluding the 2-TMS derivative of L-proline (Figure 3.7), which 
was assigned only two SIM ions, m/z 142 and 216. For a small number of compounds it was possible to choose 
four SIM ions; these include adenosine monophosphate, adipic acid, ascorbic acid, creatinine, L-DOPA, 
epinephrine, inosine, L-lysine, 3-methoxytyramine, myo-inositol and ribitol. As an illustration, Figure 3.8 shows 
a full scan mass spectrum of thymine, and the three most abundant ions m/z 113, 255 and 270 were selected. 
Figure 3.9 shows a full scan mass spectrum of β-alanine, from which three SIM ions were selected, m/z 174, 
248 and 290 were selected. The disadvantage to this spectrum was the low abundance of m/z 290.  
3.2.1. Mixture 1 
In mixture 1, all 19 compounds were identified from the full scan spectrum (Figure 3.1). The retention times of 
these compounds ranged from 11.351 to 41.671 minutes, where the first and last eluted compounds were 2-
ketobutyric acid and adenosine respectively (Table 3.4). This data was used to determine appropriate SIM ions 
for each compound (Table 3.5). 
3.2.2. Mixture 2 
In mixture 2, 17 out of the 19 compounds were identified from the full scan spectrum (Figure 3.2). The 
retention times of these compounds ranged from 10.008 to 33.767 minutes, where the first and last eluted 
compounds were lactic acid and myo-inositol respectively (Table 3.6). The two compounds that could not be 
identified were ornithine and cytidine. This data was used to determine appropriate SIM ions for each of the 17 
identified compounds (Table 3.7). 
3.2.3. Mixture 3 
In mixture 3, 17 out of the 19 compounds were identified from the full scan spectrum (Figure 3.3). The 
retention times of these compounds ranged from 14.932 to 35.147 minutes, where the first and last eluted 
compounds were methylmalonic acid and L-tryptophan respectively (Table 3.8). The two compounds that could 
not be identified were cortisol and picolinic acid. This data was used to determine appropriate SIM ions for 


























Figure 3.1: A full scan chromatogram of mixture 1 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.4. 




Table 3.4: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.1, 
based on analysis of mixture 1 on the Bruker SCION triple quadrupole GC-MS. 
 
Number        Compound 
1  Acetaminophen 
2  Adenine 
3  Adenosine 
4 L- Arabinose 
5 3,4- Dihydroxybenzeneacetic acid 
6  Fumaric acid 
7  Glycerol 
8 4- Hydroxy-L-Proline 
9 3- Hydroxybutyric acid (2TMS) 
10 3- Hydroxybutyric acid (XTMS) 
11 3- Hydroxybutyric acid (XTMS) 
12 2- Hydroxyisobutyric acid 
13  Hypoxanthine 
14  Indoleacetic acid (1TMS) 
15  Indoleacetic acid (2TMS) 
16 2- Ketobutyric acid 
17  Kynurenic acid 
18 L- Kynurenine (2TMS) 
19 L- Kynurenine (3TMS) 
20  Linoleic acid 
21 D- Mannose 
22 D- Mannose 
23 L- Serine 
24 L- Threonine 
 
Table 3.5: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 1 analysed on the 
Bruker SCION triple quadrupole GC-MS.  
 
                     Compound 
Retention 
time 




Qualifier ion 1 
(m/z) 
Qualifier ion 2 
(m/z) 
 Acetaminophen 25.037 2 206 280 295 
 Adenine 29.639 2 264 279 192 
 Adenosine 41.671 4 230 236 245 
L- Arabinose 25.965 4 103 217 307 
3,4- Dihydroxybenzeneacetic acid 28.954 3 179 267 384 
 Fumaric acid 18.449 2 245 143 133 
 Glycerol 16.708 3 117 133 205 
4- Hydroxy-L-Proline 22.853 3 230 140 304 
3- Hydroxybutyric acid 24.217 X 143 117 233 
3- Hydroxybutyric acid 24.326 X 143 159 233 
3- Hydroxybutyric acid 13.181 2 117 191 233 
2- Hydroxyisobutyric acid 12.149 2 131 205 190 
 Hypoxanthine 28.495 2 265 280 266 
 Indoleacetic acid 30.462 1 130 247 103 
 Indoleacetic acid 31.370 2 202 319 304 
2- Ketobutyric acid 11.351 1 89 188 172 
 Kynurenic acid 33.113 2 231 318 304 
L- Kynurenine 35.230 3 307 192 218 
L- Kynurenine 34.723 2 192 218 120 
 Linoleic acid 35.189 1 79 129 335 
D- Mannose 30.314 5 319 205 160 
D- Mannose 30.555 5 205 319 160 
L- Serine 23.896 X 114 276 290 







 Figure 3.2: A full scan chromatogram of mixture 2 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.6. 
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Table 3.6: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.2, 
based on analysis of mixture 2 on the Bruker SCION triple quadrupole GC-MS. 
 
Number       Compound 
1  Azelaic acid 
2  Cotinine 
3  Creatine 
4  Dopamine 
5  Ethanolamine 
6 D- Fructose 
7 D- Fructose 
8  GABA 
9 D- Galactose 
10 D- Galactose 
11 L- Glutamine 
12 Myo- Inositol 
13 L- Lactic acid 
14 L- Lysine 
15  Nicotinic acid 
16  Putrescine 
17 D- Ribose 
18  Scyllitol 
19 L- Valine 
 
 
Table 3.7: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 2 analysed on the 
Bruker SCION triple quadrupole GC-MS. 
 
                 Compound 
Retention 
time 





ion 1 (m/z) 
Qualifier 
ion 2 (m/z) 
Qualifier 
ion 3 (m/z) 
 Azelaic acid 28.194 2 129 317 201  
 Cotinine 26.576 X 98 176 118  
 Creatine 23.455 X 115 143 329  
 Dopamine 33.323 4 174 86 175  
 Ethanolamine 16.365 3 174 100 86  
D- Fructose 30.253 5 103 217 307  
D- Fructose 30.056 5 103 217 307  
 GABA 22.845 3 174 304 86  
D- Galactose 30.414 5 319 205 160  
D- Galactose 30.356 5 204 191 217  
L- Glutamine 27.923 3 156 245 128  
Myo- Inositol 33.767 6 217 305 318 191 
L- Lactic acid 10.008 1 117 191 291  
L- Lysine 30.619 4 174 156 128 317 
 Nicotinic acid 16.963 1 180 136 106  
 Putrescine 27.126 4 174 130 214  
D- Ribose 26.307 4 103 217 307  
 Scyllitol 32.759 6 217 318 191  



























Figure 3.3: A full scan chromatogram of mixture 3 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.8. 
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Table 3.8: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.3, 
based on analysis of mixture 3 on the Bruker SCION triple quadrupole GC-MS. 
 
Number    Compound 
1 Cis- Aconitic acid 
2 B- Alanine 
3  Ascorbic acid 
4  Citric acid 
5 L- Glutamic acid 
6  Glycine 
7  Homocysteine 
8  Homovanillic  acid 
9 L- Isoleucine 
10 L- Leucine 
11  Mannitol 
12  Methylmalonic acid 
13  Thymine 
14 L- Tryptophan 
15 L- Tyrosine 
16  Urea 
17  Uric acid 
 
Table 3.9: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 3 analysed on the 
Bruker SCION triple quadrupole GC-MS. 
 
                 Compound 
Retention 
time 





ion 1 (m/z) 
Qualifier 
ion 2 (m/z) 
Qualifier 
ion 3 (m/z) 
Cis- Aconitic acid 27.423 3 229 375 285  
B- Alanine 20.482 3 174 248 290  
 Ascorbic acid 29.450 X 157 173 129 316 
 Citric acid 28.925 4 273 373 347  
L- Glutamic acid 22.699 2 156 230 258  
 Glycine 17.454 3 174 248 86  
 Homocysteine 25.723 3 128 234 119  
 Homovanillic  acid 27.819 2 209 326 178  
L- Isoleucine 17.152 2 158 218 159  
L- Leucine 16.559 2 158 102 232  
 Mannitol 31.069 6 205 319 217  
 Methylmalonic acid 14.932 2 147 218 247  
 Thymine 19.924 2 255 113 270  
L- Tryptophan 35.147 2 130 218 100  
L- Tyrosine 30.933 3 218 179 280  
 Urea 15.709 2 189 130 171  
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3.2.4. Mixture 4 
In mixture 4, 13 out of the 17 compounds were identified from the full scan spectrum (Figure 3.4). The 
retention times of these compounds ranged from 11.310 to 39.307 minutes, where the first and last eluted 
compounds were L-alanine and biotin respectively (Table 3.10). The four compounds that could not be 
identified were cholesterol, pregnenolone, progesterone, and spermine. This data was used to determine 
appropriate SIM ions for each compound (Table 3.11). 
3.2.5. Mixture 5 
In mixture 5, 7 out of the 15 compounds were identified from the full scan spectrum. (Figure 3.5). The 
retention times of these compounds ranged from 22.261 to 47.003 minutes, where the first and last eluted 
compounds were adipic acid and adenosine monophosphate respectively (Table 3.12). The eight compounds 
that could not be identified were acetylcholine, agmatine, allantoin, choline, citrulline, cyancobalamin, 
glutathione and zinc. This data was used to determine appropriate SIM ions for each compound (Table 3.13). 
3.2.6. Mixture 6 
In mixture 6, 8 out of the 15 compounds were identified from the full scan spectrum (Figure 3.6). The retention 
times of these compounds ranged between 13.633 and 36.097 minutes, where the first and last eluted 
compounds were L-α-aminobutyric acid and spermidine respectively (Table 3.14).  The seven compounds that 
could not be identified were arachidonic acid, L-carnitine, L-cystine, melatonin, taurine, thiamine, and 









 Figure 3.4: A full scan chromatogram of mixture 4 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.10 
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Table 3.10: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.4, 
based on analysis of mixture 4 on the Bruker SCION triple quadrupole GC-MS. 
 
Number    Compound 
1 L- Alanine 
2 L- Asparagine 
3  Biotin 
4  Epinephrine 
5 D- Glucose 
6 D- Glucose 
7  Isocitric acid 
8 L- Methionine 
9 L- Phenylalanine 
10 L- Proline 
11 L- Proline 
12  Pyroglutamic acid 
13  Ribitol 
14  Sorbitol 
15  Succinic acid 
Table 3.11: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 4 analysed on the 
Bruker SCION triple quadrupole GC-MS. 
 
              Compound 
Retention 
time 





ion 1 (m/z) 
Qualifier 
ion 2 (m/z) 
Qualifier 
ion 3 (m/z) 
L- Alanine 11.310 2 116 190 100  
L- Asparagine 22.180 2 100 115 128  
 Biotin 39.307 3 241 189 445  
 Epinephrine 31.466 4 116 117 355 217 
D- Glucose 30.514 5 319 160 205  
D- Glucose 30.825 5 319 205 103  
 Isocitric acid 28.961 4 273 245 319  
L- Methionine 22.628 2 176 128 293  
L- Phenylalanine 24.937 2 218 192 100  
L- Proline 17.159 2 142 216   
L- Proline 24.004 X 142 186 288  
 Pyroglutamic acid 22.717 2 156 258 230  
 Ribitol 27.222 5 217 103 205 319 
 Sorbitol 31.199 6 319 205 217  







        Figure 3.5: A full scan chromatogram of mixture 5 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.12. 




Table 3.12: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.5, 
based on analysis of mixture 5 on the Bruker SCION triple quadrupole GC-MS. 
 
Table 3.13: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 5 analysed on the 
Bruker SCION triple quadrupole GC-MS. 
 
              Compound 
Retention 
time 





ion 1 (m/z) 
Qualifier 
ion 2 (m/z) 
Qualifier 
ion 3 (m/z) 
 Adenosine Monophosphate 47.003 4 169 315 230 192 
 Adipic acid 22.261 2 111 141 83 275 
L- Arginine 28.858 3 157 256 142  
 Creatinine 23.448 3 115 100 143 329 
 Inosine 40.867 4 217 230 245 281 
 Norepinephrine 34.726 5 174 355 100  



















Number            Compound 
1  Adenosine Monophosphate 
2  Adipic acid 
3 L- Arginine 
4  Creatinine 
5  Inosine 
6  Norepinephrine 


















































Figure 3.6: A full scan chromatogram of mixture 6 generated on the Bruker SCION triple quadrupole GC-MS. Numbered compounds are identified in Table 3.14. 




Table 3.14: Compounds that correspond to the numbers labelled on the mass chromatogram in Figure 3.6, based on 
analysis of mixture 6 on the Bruker SCION triple quadrupole GC-MS. 
 
Number             Compound 
1 L-α- Aminobutyric  acid 
2  Glyceric acid 
3 L- Histidine 
4 L- Dopa 
5 3- Methoxytyramine 
6  Oleic acid 
7  Oxoglutaric acid 
8  Spermidine 
Table 3.15: SIM ions chosen from the full scan mass spectrum for the compounds in mixture 6 analysed on the Bruker 
SCION triple quadrupole GC-MS. 
 
                    Compound 
Retention 
time 





ion 1 (m/z) 
Quantifier 
ion 2 (m/z) 
Quantifier 
ion 3 (m/z) 
L-α- Aminobutyric acid 13.633 2 130 131 204  
 Glyceric acid 18.240 3 189 292 133  
 Oxoglutaric acid 23.956 2 89 198 156  
L- Histidine 30.655 3 154 254 155  
3- Methoxytyramine 32.594 3 174 368 100 86 
L- Dopa 33.724 4 218 267 368 179 
 Oleic acid 35.257 1 117 129 339  







































































Figure 3.9: A full scan mass spectrum of the TMS derivative of β-alanine, profiled on the Bruker SCION triple quadrupole GC-MS 




3.3. SIM/scan analysis  
The next step to building a MS/MS database involved a SIM/scan analysis, which aims to scan for the specific 
fragment ions that were identified from the full scan analysis, to establish potential precursor ions for MS/MS. 
A SIM/scan analysis increases the sensitivity of compound identification as the mass spectrum is only scanning 
for selected ions at particular retention times. Table 3.5, 3.7, 3.9, 3.11, 3.13 and 3.15 list the SIM ions used for 
each mixture in this scan.  
 
While a fragment ion may be abundant in full scan analysis, when using those ions in a SIM/scan, the 
reproducibility may change. To confirm that a particular ion was generated during fragmentation, the ion 
chromatogram of each ion was observed, rather than the total ion chromatogram of the compound. As an 
illustration, Figure 3.10 demonstrates the SIM/scan ion chromatograms of ribitol, it shows that m/z 217, 205 
and 103 ions were all produced during fragmentation of this compound, and all three ions had relatively high 
signal/noise ratios of 330692:1, 199122:1 and 88675:1 respectively. Figure 3.11 represents the SIM/scan ion 
chromatograms of adipic acid. The peak for the SIM ion m/z 275 was absent with a signal to noise ratio of -2:1, 
however, the other three SIM ions m/z 111, 141 and 83 presented ideal peaks with relatively high signal/noise 
ratios of 76082:1, 63990:1 and 19800:1 respectively. Figure 3.12 represents the SIM/scan ion chromatograms 
of hypoxanthine, with no defined peak for any of the three SIM ions m/z 265,280 and 266. 
 
Analysing the reproducibility of each ion resulted in the selection of precursor ions for MS/MS. For some 
compounds all of the ions selected from full scan analysis were observed, while for some compounds only 1 or 
2 ions were observed. Table 3.16, 3.17, 3.18, 3.19, 3.20 and 3.21 show the precursor ions chosen for each 






































































































Figure 3.12: Ion chromatograms of the 3 SIM ions (m/z 265,280 and 266) identified from the full scan analysis of the TMS derivative of hypoxanthine on the Bruker SCION triple quadrupole GC-MS 




Table 3.16: Precursor ions chosen for each compound in mixture 1 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




 Acetaminophen 25.037 206   
 Adenine 29.639 192   
 Adenosine 41.671 230 236 245 
L- Arabinose 25.965 217 103  
3,4- Dihydroxybenzeneacetic acid 28.954 384 179 267 
 Fumaric acid 18.449 143 245 133 
 Glycerol 16.708 130 117 205 
4- Hydroxy-L-Proline 22.853 140 230  
3- Hydroxybutyric acid 24.217 117 233 143 
3- Hydroxybutyric acid 24.326 159 143 233 
3- Hydroxybutyric acid 13.181 117   
2- Hydroxyisobutyric acid 12.149 190   
 Hypoxanthine 28.495 265   
 Indoleacetic acid 30.462 247 130 103 
 Indoleacetic acid 31.370 319 202 160 
2- Ketobutyric acid 11.351 89 172 188 
 Kynurenic acid 33.113 231   
L- Kynurenine 35.230 218 192  
L- Kynurenine 34.723 218 120 192 
 Linoleic acid 35.189 79   
D- Mannose 30.314 160 319 205 
D- Mannose 30.555 205 319 160 
L- Serine 23.896 114   
L- Threonine 19.654 218 117 101 
 
Table 3.17: Precursor ions chosen for each compound in mixture 2 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




 Azelaic acid 28.194 129 201   
 Cotinine 26.576 118 98 176  
 Creatine 23.455 115 143   
 Dopamine 33.323 86 175   
 Ethanolamine 16.365 100 174 86  
D- Fructose 30.056 217 103   
D- Fructose 30.253 217 103   
 GABA 22.845 174 86   
D- Galactose 30.414 319 205 160  
D- Galactose 30.356 191 217 204  
L- Glutamine 27.923 128 156 245  
Myo- Inositol 33.767 318 191 217  
L- Lactic acid 10.008 117 191   
L- Lysine 30.619 128 174 317 156 
 Nicotinic acid 16.963 180 136 106  
 Putrescine 27.126 130 214 174  
D- Ribose 26.307 103 217   
 Scyllitol 32.759 318 191 217  















Table 3.18: Precursor ions chosen for each compound in mixture 3 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




Cis- Aconitic acid 27.423 229   
B- Alanine 20.482 174   
 Ascorbic acid 29.450 157 129 173 
 Citric acid 28.925 347   
L- Glutamic acid 22.699 156 258 230 
 Glycine 17.454 248 86 174 
 Homocysteine 25.723 128 119 234 
 Homovanillic  acid 27.819 178 209  
L- Isoleucine 17.152 218 159 158 
L- Leucine 16.559 158 102 232 
 Mannitol 31.069 319 205 217 
 Methylmalonic acid 14.932 218 147  
 Thymine 19.924 255 113  
L- Tryptophan 35.147 100 218 130 
L- Tyrosine 30.933 179 218  
 Urea 15.709 189 130  
 Uric acid 33.908 382   
 
Table 3.19: Precursor ions chosen for each compound in mixture 4 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




L- Alanine 11.310 190 116 100 
L- Asparagine 22.180 115 100 128 
 Biotin 39.307 241 189  
D- D-Glucose 30.825 103 205  
 Epinephrine 31.466 116 355  
D- Glucose 30.514 205 160  
 Isocitric acid 28.961 245   
L- Methionine 22.628 128 176  
L- Phenylalanine 24.937 100 192 218 
L- Proline 17.159 142   
L- Proline 24.004 186   
 Pyroglutamic acid 22.717 258 230 156 
 Ribitol 27.222 217 103 205 
 Sorbitol 31.199 217 205 319 
 Succinic acid 17.611 147 129  
 
Table 3.20: Precursor ions chosen for each compound in mixture 5 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




 Adenosine Monophosphate 47.003 315 169 192 
 Adipic acid 22.261 111 141 83 
L- Arginine 28.858 142 157  
 Creatinine 23.448 100 143 115 
 Inosine 40.867 217 245  
 Norepinephrine 34.726 174 100 355 












Table 3.21: Precursor ions chosen for each compound in mixture 6 based on data generated from SIM/scan 
analysis on the Bruker SCION triple quadrupole GC-MS. 
 




L-α- Aminobutyric  acid 13.633 204 130 131 
L- Dopa 33.724 267 218 368 
 Glyceric acid 18.240 133 189 292 
L- Histidine 30.655 154   
3- Methoxytyramine 32.594 174 100  
 Oleic acid 35.257 145 129 117 
 Oxoglutaric acid 23.956 89 198 156 
 Spermidine 36.097 174 144 116 
3.4. Product ion scan analysis 
Following the identification of precursor ions from the SIM/scan analysis (Table 3.16-3.21), each mixture was 
analysed using a product ion scan. This scan aims to identify the product ions that are produced during 
dissociation of precursor ions. From this scan, the MRM transitions were selected. To identify the product ions 
produced from the dissociation of a precursor ion, the ion chromatogram of each precursor ion was observed. 
Each precursor ion was analysed using five different collision energies (5, 15, 25, 35 and 45 V). For many 
compounds, the same transitions were generated from more than one collision energy, therefore in some 
cases multiple collision energies were included in the MRM scan. For other potential MRMs, if one collision 
energy in particular generated a higher signal/noise ratio, that energy was selected for the transition, rather 
than multiple collision energies, full details in Table 6.1-6.6 in the Appendix shows all transitions identified for 
each compound. 
 
For illustration, Figure 3.13 shows the ion chromatograms of the m/z 218, 267 and 386 precursor ions at a 5 V 
collision energy of L-DOPA. A peak was evident for all three ions, with signal/noise ratios of 90712:1, 4 x 10
8
:1 
and 1 x 10
8
:1 respectively. Figure 3.14 shows the product ion mass spectrum of the m/z 368 precursor ion of L-
DOPA, showing considerable dissociation at this collision energy. The four transitions 368>149, 368>217, 
368>218 and 368>271 were selected. Figure 3.15 shows the ion chromatograms of the m/z 180, 106 and 136 
precursor ions of nicotinic acid at a 15 V collision energy. A peak was evident for all three ions, with 
signal/noise ratios of 90219:1, 40360:1 and 38719:1 respectively. Figure 3.16 shows the product ion scan mass 
spectrum of the m/z 136 precursor ion of nicotinic acid. The four transitions 136>83, 136>94, 136>108 and 




136>132 were selected. Although the m/z 81 product ion had a larger abundance than the m/z 132 product 
ion, m/z 132 was selected because of its larger mass. Figure 3.17 shows the ion chromatogram of the m/z 154 
precursor ion at 35 V collision energy of L-histidine. No peak is evident in the ion chromatogram. Figure 3.18 
shows the product ion scan mass spectrum of the m/z 154 precursor ion of L-histidine; only one product ion 
was generated from the dissociation of this ion. Although the reproducibility of the m/z 154 precursor ion was 

























































































Figure 3.18: Mass spectrum showing product ions generated from the dissociation of the m/z 154 precursor ion of the TMS derivative of L-histidine at 35 V collision energy on the Bruker SCION triple quadrupole GC-MS




3.5. MRM scan analysis 
Following the identification of possible mass transitions in 3.4, a MRM method was built for each mixture using 
the transitions for each compound (full details in Table 6.1-6.6 in the Appendix). Testing the possible mass 
transitions aims to identify up to five optimal mass transitions and corresponding collision energies for each 
compound. Determining the optimal transitions was achieved by overlaying a maximum of 10 transitions 
selected in 3.4 and analysed in the MRM scan for each compound. This approach was implemented for all 
compounds and Table 3.22-3.27 demonstrates the optimal transitions and their collision energies for each 
mixture, representing the final MS/MS method for each mixture. Several compounds had fewer than five 
transitions, which was a result of poor reproducibility of the transitions, or the limitation of possible transitions 
identified in 3.4. 
 
 As an illustration, Figure 3.19 shows the overlaid transitions of nicotinic acid. 12 transitions were chosen in 3.4, 
but upon observation, six were most reproducible, and two were the same, but with different collision energy. 
The ideal transitions for nicotinic acid were 136>132, 180>78, 180>106 and 180>136 at 15 V, 136>106 at 25 V 
and 180>78 at 45 V. The signal/noise ratios were 223673:1, 622029:1, 2 x 10
6
:1, 427673:1, 13664:1 and 
485703:1 respectively.  When deciding which collision energy to use for identical transitions, the energy which 
gave a higher signal/noise ratio was chosen, for example, for the transition 180>78, 15 V was the optimal 
energy. Figure 3.20 shows the ion chromatograms of the four initial transitions chosen for azelaic acid. For this 
compound only three transitions were optimal: 129>75 at 25 V and 201>83 and 201>111 at 5 V. A peak was 
evident for 201>75 at 15 V, and while its shape was not optimal, this transition was still included in the 
method. The signal/noise ratios of these transitions were 52565:1, 276786:1, 196751:1 and 6453:1 
respectively. Figure 3.21 shows the ion chromatogram of urea, showing that all five transitions initially selected 
were not optimal. However, while the peak shape was poor, the transition of 189>145 at 15 V did generate a 
peak, and therefore was the only transition chosen for this compound. The signal/noise ratio for this 
compound was 7446:1.  
  




Table 3.22: Final MS/MS method built for mixture 1 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound.  
 



































































3- Hydroxybutyric acid 24.326 
143>99 15 
143>75 15 
3- Hydroxybutyric acid 13.181 117>75 35 











































































Table 3.22 continued: Final MS/MS method built for mixture 1 on the Bruker SCION triple quadrupole GC-MS, 
containing a maximum of five optimal transitions and optimal collision energies for each compound.  
 











































Table 3.23: Final MS/MS method built for mixture 2 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound. 
 







































D- Fructose 30.056 
103>73 5 
103>91 15 










































































































Table 3.24: Final MS/MS method built for mixture 3 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound.   
 
            Compound Retention Time (min) Transition Collision energy (V) 
Cis- Aconitic acid  27.423 
229>133 15 
229>151 15 























































































L- Tyrosine 30.933 
179>73 5 
218>100 5 
 Urea 15.709 189>145 15 
 Uric acid 33.908 382>300 15 
 
  




Table 3.25: Final MS/MS method built for mixture 4 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound. 
 
        Compound Retention Time (min) Transition Collision energy (V) 









































 Isocitric acid 28.961 
245>133 15 
245>149 15 












L- Proline 17.159 142>73 15 
L- Proline 24.004 186>114 35 












































Table 3.26: Final MS/MS method built for mixture 5 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound. 
 
               Compound Retention Time (min) Transition Collision energy (V) 

























































Table 3.27: Final MS/MS method built for mixture 6 on the Bruker SCION triple quadrupole GC-MS, containing a 
maximum of five optimal transitions and optimal collision energies for each compound. 
 







































































































































































Figure 3.21: An overlaid ion chromatogram of 5 transitions analysed in an MRM scan of the TMS derivative of urea on the Bruker SCION triple quadrupole GC-MS 




3.6. Development of final method  
3.6.1. Method optimisation: Phase 1 
To confirm the final MS/MS method developed for each mixture, the mixtures were analysed using the optimal 
transitions chosen in 3.5 (Table 3.22-3.27). Based on the signal/noise ratios, it appears that most compounds 
were successfully detected (Table 3.28-3.33).  
 
For all but one of the compounds that eluted at multiple retention times, one derivatisation product appeared 
to be more consistent.  For example, the derivative of 3-hydroxybutyric acid that eluted at 24.217 minutes had 
a signal/noise ratio of 23587:1, whereas the derivative that eluted at 24.326 minutes had a ratio of 8741:1. The 
1-TMS derivative of indoleacetic acid had a signal/noise ratio of 4468:1, whereas the 2-TMS derivative had a 
ratio of 215022:1. The D-mannose isomer that eluted at 30.314 minutes had a signal/noise ratio of 183888:1, 
where as the isomer which eluted at 30.555 minutes had a ratio of 1966:1. The TMS derivative of L-proline that 
eluted at 24.004 minutes, and the TMS derivatives of uric acid and pyroglutamic acid were unidentified.  
Table 3.28: The signal/noise ratios of compounds in mixture 1 analysed using the final MS/MS method for 
mixture 1 on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound Retention time (min) Signal/noise ratio (:1) 
 Acetaminophen 25.037 1871324 
 Adenine 29.639 296645 
 Adenosine 41.671 99297 
L- Arabinose 25.965 15462 
3,4- Dihydroxybenzeneacetic acid 28.954 742652 
 Fumaric acid 18.449 674560 
 Glycerol 16.708 190079 
4- Hydroxy-L-Proline 22.853 1679240 
3- Hydroxybutyric acid 13.181 3221 
3- Hydroxybutyric acid 24.217 23587 
3- Hydroxybutyric acid 24.326 8741 
2- Hydroxyisobutyric acid 12.149 22164 
 Hypoxanthine 28.495 26563 
 Indoleacetic acid 30.462 4468 
 Indoleacetic acid 31.370 215022 
2- Ketobutyric acid 11.351 51855 
 Kynurenic acid 33.113 1522 
L- Kynurenine 34.723 2130 
L- Kynurenine 35.230 61251 
 Linoleic acid 35.189 9026 
D- Mannose 30.314 183888 
D- Mannose 30.555 1966 
L- Serine 23.896 94660 








Table 3.29: T The signal/noise ratios of compounds in mixture 2 analysed using the final MS/MS method for 
mixture 2 on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound Retention time (min) Signal/noise ratio (:1) 
 Azelaic acid 28.194 81563 
 Cotinine 26.576 5889 
 Creatine 23.455 26170 
 Dopamine 33.323 27697 
 Ethanolamine 16.365 41203 
D- Fructose 30.056 104412 
D- Fructose 30.253 38 
 GABA 22.845 26492 
D- Galactose 30.356 227 
D- Galactose 30.414 694 
L- Glutamine 27.923 48283 
Myo- Inositol 33.767 7060 
L- Lactic acid 10.008 150 
L- Lysine 30.619 798 
 Nicotinic acid 16.963 2026427 
 Putrescine 27.126 25027 
D- Ribose 26.307 22728 
 Scyllitol 32.759 16160 
L- Valine 14.956 77890 
 
Table 3.30: The signal/noise ratios of compounds in mixture 3 analysed using the final MS/MS method for 
mixture 3 on the Bruker SCION triple quadrupole GC-MS. 
 
          Compound Retention time (min) Signal/noise ratio (:1) 
Cis- Aconitic acid 27.423 55262 
B- Alanine 20.482 51004 
 Ascorbic acid 29.450 22814 
 Citric acid 28.925 74002 
L- Glutamic acid 22.699 138430 
 Glycine 17.454 16771 
 Homocysteine 25.723 267646 
 Homovanillic  acid 27.819 44584 
L- L-Isoleucine 17.152 395383 
L- Leucine 16.559 42051 
 Mannitol 31.069 894 
 Methylmalonic acid 14.932 71638 
 Thymine 19.924 36296 
L- Tryptophan 35.147 10814 
L- Tyrosine 30.933 7686 
 Urea 15.709 16 
 Uric acid 33.908 N/A 
 
Table 3.31: The signal/noise ratios of compounds in mixture 4 analysed using the final MS/MS method for 
mixture 4 on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound Retention time (min) Signal/noise ratio (:1) 
L- Alanine 11.310 157492 
L- Asparagine 22.180 139627 
 Biotin 39.307 293943 
 Epinephrine 31.466 58535 
D- Glucose 30.514 53261 
D- Glucose 30.825 1888 
 Isocitric acid 28.961 17437 
L- Methionine 22.628 353742 
L- Phenylalanine 24.937 55296 
L- Proline 17.159 1350805 
L- Proline 24.004 N/A 
 Pyroglutamic acid 22.717 N/A 
 Ribitol 27.222 128413 
 Sorbitol 31.199 4172 
 Succinic acid 17.611 128742 




Table 3.32: The signal/noise ratios of compounds in mixture 5 analysed using the final MS/MS method on the 
mixture 5 Bruker SCION triple quadrupole GC-MS. 
 
           Compound Retention time (min) Signal/noise ratio (:1) 
 Adenosine Monophosphate 47.003 66 
 Adipic acid 22.261 47756 
L- Arginine 28.858 4757 
 Creatinine 23.448 4958 
 Inosine 40.867 195340 
 Norepinephrine 34.726 309725 
 Quinolinic acid 27.044 719985 
 
Table 3.33: The signal/noise ratios of compounds in mixture 6 analysed using the final MS/MS method on the 
mixture 6 Bruker SCION triple quadrupole GC-MS. 
 
           Compound Retention time (min) Signal/noise ratio (:1) 
L-α- Aminobutyric  acid 13.633 207119 
 Glyceric acid 18.240 35166 
 Oxoglutaric acid 23.956 670573 
L- Histidine 30.655 471 
3- Methoxytyramine 32.594 34181 
L- Dopa 33.724 1783 
 Oleic acid 35.257 27802 
 Spermidine 36.097 6025 
 
Each method was then tested on a combined mixture of all standards to confirm any compounds that may be 
lost due to cross-reaction with other compounds (Table 3.34-3.39). A total of 12 compounds among the 6 
methods could not be identified from the combined mixture. In mixture 1, both indoleacetic acid derivatives 
and kynurenic acid were not identified. In mixture 2, the D-fructose isomer that eluted at 30.253 minutes, the 
D-galactose isomer that eluted at 30.356 and L-glutamine were not identified. In mixture 3, L-tryptophan, urea 
and uric acid were not identified. In mixtures 4, 5 and 6, the only compounds that could not be identified from 
the combined mixture were the D-glucose isomer that eluted at 30.825 minutes, adenosine monophosphate 
and spermidine respectively. Furthermore, it appears that the signal/noise ratio decreased for a majority of the 



















Table 3.34: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 1 on the Bruker SCION triple quadrupole GC-MS. 
 
           Compound 
Retention Time 
(min) 
Identified Not identified 
Signal/noise ratio 
(:1) 
 Acetaminophen 25.037 ✓  36191 
 Adenine 29.639 ✓  2454 
 Adenosine 41.671 ✓  13882 
L- Arabinose 25.965 ✓  24977 
3,4- Dihydroxybenzeneacetic acid 28.954 ✓  67054 
 Fumaric acid 18.449 ✓  19045 
 Glycerol 16.708 ✓  17351 
4- Hydroxy-L-Proline 22.853 ✓  82346 
3- Hydroxybutyric acid 24.217 ✓  3879 
3- Hydroxybutyric acid 24.326 ✓  498 
3- Hydroxybutyric acid 13.181 ✓  220 
2- Hydroxyisobutyric acid 12.149 ✓  64 
 Hypoxanthine 28.495 ✓  272 
 Indoleacetic acid 30.462  ✓ N/A 
 Indoleacetic acid 31.370  ✓ N/A 
2- Ketobutyric acid 11.351 ✓  1549 
 Kynurenic acid 33.113  ✓ N/A 
L- Kynurenine 35.230 ✓  6161 
L- Kynurenine 34.723 ✓  558 
 Linoleic acid 35.189 ✓  327 
D- Mannose 30.314 ✓  4272 
D- Mannose 30.555 ✓  135 
L- Serine 23.896 ✓  63 
L- Threonine 19.654 ✓  21890 
 
Table 3.35: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 2 on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound 
Retention Time 
(min) 
Identified Not identified 
Signal/noise ratio 
(:1) 
 Azelaic acid 28.194 ✓  8101 
 Cotinine 26.576 ✓  280 
 Creatine 23.455 ✓  7287 
 Dopamine 33.323 ✓  99253 
 Ethanolamine 16.365 ✓  6042 
D- Fructose 30.056 ✓  2872 
D- Fructose 30.253  ✓ N/A 
 GABA 22.845 ✓  11233 
D- Galactose 30.414 ✓  16 
D- Galactose 30.356  ✓ N/A 
L- Glutamine 27.923  ✓ N/A 
Myo- Inositol 33.767 ✓  64323 
L- Lactic acid 10.008 ✓  152 
L- Lysine 30.619 ✓  427 
 Nicotinic acid 16.963 ✓  15953 
 Putrescine 27.126 ✓  14247 
D- Ribose 26.307 ✓  30416 
 Scyllitol 32.759 ✓  57359 
















Table 3.36: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 3 on the Bruker SCION triple quadrupole GC-MS. 
 
          Compound 
Retention Time 
(min) 
Identified Not identified 
Signal/noise ratio 
(:1) 
Cis- Aconitic acid 27.423 ✓  2186 
B- Alanine 20.482 ✓  7756 
 Ascorbic acid 29.450 ✓  4657 
 Citric acid 28.925 ✓  26713 
L- Glutamic acid 22.699 ✓  121511 
 Glycine 17.454 ✓  4663 
 Homocysteine 25.723 ✓  20190 
 Homovanillic  acid 27.819 ✓  11236 
L- Isoleucine 17.152 ✓  63971 
L- Leucine 16.559 ✓  1599 
 Mannitol 31.069 ✓  1174 
 Methylmalonic acid 14.932 ✓  9537 
 Thymine 19.924 ✓  28733 
L- Tryptophan 35.147  ✓ N/A 
L- Tyrosine 30.933 ✓  554 
 Urea 15.709  ✓ N/A 
 Uric acid 33.908  ✓ N/A 
Table 3.37: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 4 on the Bruker SCION triple quadrupole GC-MS. 
 
        Compound 
Retention Time 
(min) 
Identified Not identified Signal/noise ratio 
(:1) 
L- Alanine 11.310 ✓  3694 
L- Asparagine 22.180 ✓  1439 
 Biotin 39.307 ✓  13142 
 Epinephrine 31.466 ✓  6771 
D- Glucose 30.514 ✓  84 
D- Glucose 30.825  ✓ N/A 
 Isocitric acid 28.961 ✓  1077 
L- Methionine 22.628 ✓  18673 
L- Phenylalanine 24.937 ✓  3241 
L- Proline 17.159 ✓  73354 
L- Proline 24.004 ✓  636 
 Pyroglutamic acid 22.717 ✓  2686 
 Ribitol 27.222 ✓  44441 
 Sorbitol 31.199 ✓  8476 
 Succinic acid 17.611 ✓  1241 
Table 3.38: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 5 on the Bruker SCION triple quadrupole GC-MS. 
 
             Compound 
Retention Time 
(min) 
Identified Not identified 
Signal/noise ratio 
(:1) 
 Adenosine Monophosphate 47.003  ✓ N/A 
 Adipic acid 22.261 ✓  3124 
L- Arginine 28.858 ✓  1252 
 Creatinine 23.448 ✓  6119 
 Inosine 40.867 ✓  2578 
 Norepinephrine 34.726 ✓  36840 











Table 3.39: Compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method for mixture 6 on the Bruker SCION triple quadrupole GC-MS. 
 
Compound Retention Time 
(min) 
Identified Not identified 
Signal/noise ratio 
(:1) 
L-α- Aminobutyric  acid 13.633 ✓  36379 
L- Dopa 33.724 ✓  12015 
 Glyceric acid 18.240 ✓  1583 
L- Histidine 30.655 ✓  601 
3- Methoxytyramine 32.594 ✓  44568 
 Oleic acid 35.257 ✓  11576 
 Oxoglutaric acid 23.956 ✓  9593 
 Spermidine 36.097  ✓ N/A 
3.6.2. Method optimisation: Phase 2  
Once the MS/MS method for each mixture was established, a final MS/MS method combining all six methods 
was developed. To identify any issues, each mixture was analysed with the combined method (Table 3.40-
3.45). Knowing which compounds were included in each mixture meant that if the combined method identified 
a compound that was not included in the mixture, this may indicate possible contamination or an artefact. 
Differentiating an artefact from contamination was achieved using the comparison technique shown in Figure 
3.22. When a compound was identified in a mixture in which it was not included, the chromatograms of 
multiple mixtures were overlaid for that compound. If the peak in each mixture lined up, this was considered 
contamination. If the peak varied from that in the mixture that originally contained the compound, the 
compound was considered an artefact. Figure 3.22 shows an example of an artefact, inosine was initially 
included in mixture 5, and observing the chromatogram it appears the peak for mixture 5 has a slightly longer 
retention time than the apparent inosine peak in the other mixtures, illustrating how artefacts were 
distinguished from contamination.  
 
A total of 23 artefacts were determined and initially identified as the following compounds: acetaminophen, 
adenine, adenosine, adipic acid, azelaic acid, ethanolamine, the D-fructose isomer that eluted at 30.056 
minutes, fumaric acid, glycerol, hypoxanthine, inosine, L-isoleucine, kynurenic acid, methylmalonic acid, 
nicotinic acid, oleic acid, the 2-TMS derivative of L-proline, quinolinic acid, ribitol, succinic acid, L-threonine, L-
tyrosine and L-valine. Furthermore, sorbitol contamination was found in mixtures 1, 5 and 6, and homocysteine 
contamination was found in mixtures 4, 5 and 6. Multiple compounds were not identified in this analysis, 
including the D-fructose isomer at the retention time of 30.253 minutes, the D-galactose isomer at the 




retention time of 30.356 minutes, glycine, 2-hydroxyisobutryic acid, the 1-TMS derivative of indoleacetic acid, 
2-ketobutyric acid, the 2-TMS derivative of L-proline, spermidine, urea and uric acid,  
Table 3.40: Compounds identified, not identified or an artefact from analysis of mixture 1 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
           Compound 
Retention time 
(min) 
Identified Not identified Artefact 
 Acetaminophen 25.037 ✓   
 Adenine 29.639 ✓   
 Adenosine 41.671 ✓   
L- Arabinose 25.965 ✓   
3,4- Dihydroxybenzeneacetic acid 28.954 ✓   
 Fumaric acid 18.449 ✓   
 Glycerol 16.708 ✓   
4- Hydroxy-L-Proline 22.853 ✓   
3- Hydroxybutyric acid 24.217 ✓   
3- Hydroxybutyric acid 24.326 ✓   
3- Hydroxybutyric acid 13.181 ✓   
2- Hydroxyisobutyric acid 12.149  ✓  
 Hypoxanthine 28.495 ✓   
 Indoleacetic acid 30.462  ✓  
 Indoleacetic acid 31.370 ✓   
2- Ketobutyric acid 11.351  ✓  
 Kynurenic acid 33.113 ✓   
L- Kynurenine 35.230 ✓   
L- Kynurenine 34.723 ✓   
 Linoleic acid 35.189 ✓   
D- Mannose 30.314 ✓   
D- Mannose 30.555 ✓   
L- Serine 23.896 ✓   
L- Threonine 19.654 ✓   
 Adipic acid 22.261   ✓ 
 Azelaic acid 28.194   ✓ 
 Ethanolamine 16.365   ✓ 
D- Fructose 30.056   ✓ 
 Inosine 40.867   ✓ 
L- Isoleucine 17.152   ✓ 
 Methylmalonic acid 14.932   ✓ 
 Nicotinic acid 16.963   ✓ 
 Oleic acid 35.257   ✓ 
L- Phenylalanine 24.937   ✓ 
L- Proline 17.159   ✓ 
 Quinolinic acid 27.044   ✓ 
 Ribitol 27.222   ✓ 
 Sorbitol 31.199 ✓   
 Succinic acid 17.611   ✓ 
L- Tyrosine 30.933   ✓ 

















Table 3.41: Compounds identified, not identified or an artefact from analysis of mixture 2 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound 
Retention time 
(min) 
Identified Not identified Artefact 
 Azelaic acid 28.194 ✓   
 Cotinine 26.576 ✓   
 Creatine 23.455 ✓   
 Dopamine 33.323 ✓   
 Ethanolamine 16.365 ✓   
D- Fructose 30.056 ✓   
D- Fructose 30.253  ✓  
 GABA 22.845 ✓   
D- Galactose 30.414 ✓   
D- Galactose 30.356  ✓  
L- Glutamine 27.923 ✓   
Myo- Inositol 33.767 ✓   
L- Lactic acid 10.008 ✓   
L- Lysine 30.619 ✓   
 Nicotinic acid 16.963 ✓   
 Putrescine 27.126 ✓   
D- Ribose 26.307 ✓   
 Scyllitol 32.759 ✓   
L- Valine 14.956 ✓   
 Acetaminophen 25.037   ✓ 
 Adenine 29.639   ✓ 
 Adenosine 41.671   ✓ 
 Adipic acid 22.261   ✓ 
 Fumaric acid 18.449   ✓ 
 Glycerol 16.708   ✓ 
 Hypoxanthine 28.495   ✓ 
 Inosine 40.867   ✓ 
L- Isoleucine  17.152   ✓ 
 Kynurenic acid 33.113   ✓ 
 Methylmalonic acid 14.932   ✓ 
 Oleic acid 35.257   ✓ 
L- Phenylalanine 24.937   ✓ 
L- Proline 17.159   ✓ 
 Quinolinic acid 27.044   ✓ 
 Ribitol 27.222   ✓ 
 Succinic acid 17.611   ✓ 
L- Threonine 19.654   ✓ 
























Table 3.42: Compounds identified, not identified or an artefact from analysis of mixture 3 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
Compound Retention time 
(min) 
Identified Not identified Artefact 
Cis- Aconitic acid 27.423 ✓   
B- Alanine 20.482 ✓   
 Ascorbic acid 29.450 ✓   
 Citric acid 28.925 ✓   
L- Glutamic acid 22.699 ✓   
 Glycine 17.454  ✓  
 Homocysteine 25.723 ✓   
 Homovanillic  acid 27.819 ✓   
L- L-Isoleucine 17.152 ✓   
L- Leucine 16.559 ✓   
 Mannitol 31.069 ✓   
 Methylmalonic acid 14.932 ✓   
 Thymine 19.924 ✓   
L- Tryptophan 35.147 ✓   
L- Tyrosine 30.933 ✓   
 Urea 15.709  ✓  
 Uric acid 33.908  ✓  
 Adenine 29.639   ✓ 
 Adenosine 41.671   ✓ 
 Adipic acid 22.261   ✓ 
 Azelaic acid 28.194   ✓ 
 Ethanolamine 16.365   ✓ 
D- Fructose 30.056   ✓ 
 Fumaric acid 18.449   ✓ 
 Glycerol 16.708   ✓ 
 Hypoxanthine 28.495   ✓ 
 Inosine 40.867   ✓ 
 Kynurenic acid 33.113   ✓ 
 Nicotinic acid 16.963   ✓ 
 Oleic acid 35.257   ✓ 
L- Phenylalanine 24.937   ✓ 
L- Proline 17.159   ✓ 
 Quinolinic acid 27.044   ✓ 
L- Threonine 19.654   ✓ 



























Table 3.43: Compounds identified, not identified or an artefact from analysis of mixture 4 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
        Compound 
Retention time 
(min) 
Identified Not identified Artefact 
L- Alanine 11.310 ✓   
L- Asparagine 22.180 ✓   
 Biotin 39.307 ✓   
 Epinephrine 31.466 ✓   
D- Glucose 30.514 ✓   
D- Glucose 30.825 ✓   
 Isocitric acid 28.961 ✓   
L- Methionine 22.628 ✓   
L- Phenylalanine 24.937 ✓   
L- Proline 17.159 ✓   
L- Proline 24.004  ✓  
 Pyroglutamic acid 22.717 ✓   
 Ribitol 27.222 ✓   
 Sorbitol 31.199 ✓   
 Succinic acid 17.611 ✓   
 Adenine 29.639   ✓ 
 Adenosine  41.671   ✓ 
 Adipic acid 22.261   ✓ 
 Azelaic acid 28.194   ✓ 
 Ethanolamine 16.365   ✓ 
D- Fructose 30.056   ✓ 
 Fumaric acid 18.449   ✓ 
 Glycerol 16.708   ✓ 
 Homocysteine 25.723 ✓   
 Hypoxanthine 28.495   ✓ 
 Inosine  40.867   ✓ 
L Isoleucine 17.152   ✓ 
 Kynurenic acid 33.113   ✓ 
 Methylmalonic acid 14.932   ✓ 
 Nicotinic acid 16.963   ✓ 
 Oleic acid 35.257   ✓ 
 Quinolinic acid 27.044   ✓ 
L- Threonine 19.654   ✓ 
L- Tyrosine 30.933   ✓ 




















Table 3.44: Compounds identified, not identified or an artefact from analysis of mixture 5 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
Compound Retention time 
(min) 
Identified Not identified Artefact 
 Adenosine Monophosphate 47.003 ✓   
 Adipic acid 22.261 ✓   
L- Arginine 28.858 ✓   
 Creatinine 23.448 ✓   
 Inosine 40.867 ✓   
 Norepinephrine 34.726 ✓   
 Quinolinic acid 27.044 ✓   
 Adenine 29.639   ✓ 
 Adenosine 41.671   ✓ 
 Azelaic acid 28.194   ✓ 
 D-Fructose 30.056   ✓ 
 Ethanolamine 16.365   ✓ 
 Fumaric acid 18.449   ✓ 
 Glycerol 16.708   ✓ 
 Homocysteine 25.723 ✓   
 Hypoxanthine 28.495   ✓ 
L Isoleucine 17.152   ✓ 
 Kynurenic acid 33.113   ✓ 
 Methylmalonic acid 14.932   ✓ 
 Nicotinic acid 16.963   ✓ 
 Oleic acid 35.257   ✓ 
L- Phenylalanine 24.937   ✓ 
L- Proline  17.159   ✓ 
 Sorbitol 31.199 ✓   
 Succinic acid 17.611   ✓ 
L- Threonine 19.654   ✓ 
L- Tyrosine 30.933   ✓ 
L- Valine 14.956   ✓ 
Table 3.45: Compounds identified, not identified or an artefact from analysis of mixture 6 using the final 
MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
         Compound Retention time 
(min) 
Identified Not identified Artefact 
L-α- Aminobutyric  acid 13.633 ✓   
L- Dopa 33.724 ✓   
 Glyceric acid 18.240 ✓   
L- Histidine 30.655 ✓   
3- Methoxytyramine 32.594 ✓   
 Oleic acid 35.257 ✓   
 Oxoglutaric acid 23.956 ✓   
 Spermidine 36.097  ✓  
 Adenine 29.639   ✓ 
 Adenosine 41.671   ✓ 
 Adipic acid 22.261   ✓ 
 Azelaic acid 28.194   ✓ 
 Ethanolamine 16.365   ✓ 
D- Fructose 30.056   ✓ 
 Fumaric acid 18.449   ✓ 
 Glycerol 16.708   ✓ 
 Homocysteine 25.723 ✓   
 Inosine 40.867   ✓ 
L Isoleucine 17.152   ✓ 
 Kynurenic acid 33.113   ✓ 
 Methylmalonic acid 14.932   ✓ 
 Nicotinic acid 16.963   ✓ 
L- Phenylalanine 24.937   ✓ 
L- Proline 17.159   ✓ 
 Quinolinic acid 27.044   ✓ 
 Sorbitol 31.199 ✓   
 Succinic acid 17.611   ✓ 
L- Threonine 19.654   ✓ 
L- Tyrosine 30.933   ✓ 


























Figure 3.22: An overlaid chromatogram of an unidentified peak being identified as inosine on the Bruker SCION triple quadrupole GC-MS., note that the peak in mixture 5 has a longer retention time. 




To conclude method development, a combined mixture of all standards was analysed using the final MS/MS 
method. Compounds that could not be identified using the final mixture methods in 3.6.1 and using this 
method in 3.6.2 were also not identified from this mixture. These compounds included adenosine 
monophosphate, the D-fructose isomer that eluted at 30.253 minutes, the D-galactose isomer that eluted at 
30.356 minutes, L-glutamine, glycine, 2-hydroxyisobutyric acid, both indoleacetic acid derivatives, kynurenic 
acid, the 2-TMS derivative of L-proline, spermidine, L-tryptophan, urea and uric acid. Furthermore, the 
signal/noise ratio decreased for most compounds.  
 
Table 3.46: The compounds identified, not identified and their signal/noise ratios from the analysis of the 
combined mixture using the final MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
          Compound Retention time 
(min) 
Identified Not identified Signal/noise ratio 
(:1) 
 Acetaminophen 25.037 ✓  24787 
Cis- Aconitic acid 27.423 ✓  1241 
 Adenine 29.639 ✓  3246 
 Adenosine 41.671 ✓  7213 
 Adenosine Monophosphate 47.003  ✓ N/A 
 Adipic acid 22.261 ✓  2509 
B- Alanine 20.482 ✓  8642 
L- Alanine 11.310 ✓  3584 
L-α- Aminobutyric acid 13.633 ✓  25883 
L- Arabinose 25.965 ✓  15841 
L- Arginine 28.858 ✓  767 
 Ascorbic acid 29.450 ✓  3422 
L- Asparagine 22.180 ✓  1118 
 Azelaic acid 28.194 ✓  8204 
 Biotin 39.307 ✓  13674 
 Citric acid 28.925 ✓  61782 
 Cotinine 26.576 ✓  352 
 Creatine 23.455 ✓  7710 
 Creatinine 23.448 ✓  7821 
3,4- Dihydroxybenzeneacetic acid 28.954 ✓  20820 
L- Dopa 33.724 ✓  9751 
 Dopamine 33.323 ✓  112937 
 Epinephrine 31.466 ✓  6964 
 Ethanolamine 16.365 ✓  4874 
D- Fructose 30.056 ✓  2487 
D- Fructose 30.253  ✓ N/A 
 Fumaric acid 18.449 ✓  21941 
 GABA 22.845 ✓  14311 
D- Galactose 30.414 ✓  17 
D- Galactose 30.356  ✓ N/A 
D- Glucose 30.514 ✓  12 
D- Glucose 30.825  ✓ N/A 
L- Glutamic acid 22.699 ✓  64612 
L- Glutamine 27.923  ✓ N/A 
 Glyceric acid 18.240 ✓  2032 
 Glycerol 16.708 ✓  10034 
 Glycine 17.454  ✓ N/A 
L- Histidine 30.655 ✓  158 
 Homocysteine 25.723 ✓  35123 
 Homovanillic  acid 27.819 ✓  12366 
4- Hydroxy-L-Proline 22.853 ✓  136612 
3- Hydroxybutyric acid 24.217 ✓  380 
3- Hydroxybutyric acid 24.326 ✓  4454 
3- Hydroxybutyric acid 13.181 ✓  236 
2- Hydroxyisobutyric acid 12.149  ✓ N/A 




Table 3.46 continued: The compounds identified, not identified and their signal/noise ratios from the analysis 
of the combined mixture using the final MS/MS method on the Bruker SCION triple quadrupole GC-MS. 
 
 Hypoxanthine 28.495 ✓  150 
 Indoleacetic acid 30.462  ✓ N/A 
 Indoleacetic acid 31.370  ✓ N/A 
 Inosine 40.867 ✓  2207 
Myo- Inositol 33.767 ✓  72752 
 Isocitric acid 28.961 ✓  N/A 
L- Isoleucine 17.152 ✓  34826 
2- Ketobutyric acid 11.351 ✓  2264 
 Kynurenic acid 33.113  ✓ N/A 
L- Kynurenine 35.230 ✓  3620 
L- Kynurenine 34.723 ✓  510 
L- Lactic acid 10.008 ✓  187 
L- Leucine 16.559 ✓  507 
 Linoleic acid 35.189 ✓  134 
L- Lysine 30.619 ✓  77 
 Mannitol 31.069 ✓  60 
D- Mannose 30.314 ✓  2250 
D- Mannose 30.555 ✓  N/A 
L- Methionine 22.628 ✓  18211 
3- Methoxytyramine 32.594 ✓  45360 
 Methylmalonic acid 14.932 ✓  8081 
 Nicotinic acid 16.963 ✓  14683 
 Norepinephrine 34.726 ✓  26160 
 Oleic acid 35.257 ✓  5507 
 Oxoglutaric acid 23.956 ✓  7614 
L- Phenylalanine 24.937 ✓  1730 
L- Proline 17.159 ✓  26833 
L- Proline 24.004  ✓ N/A 
 Putrescine 27.126 ✓  10029 
 Pyroglutamic acid 22.717 ✓  8985 
 Quinolinic acid 27.044 ✓  10043 
 Ribitol 27.222 ✓  7529 
D- Ribose 26.307 ✓  21826 
 Scyllitol 32.759 ✓  37957 
L- Serine 23.896 ✓  44 
 Sorbitol 31.199 ✓  3642 
 Spermidine 36.097  ✓ N/A 
 Succinic acid 17.611 ✓  1186 
L- Threonine 19.654 ✓  26489 
 Thymine 19.924 ✓  18064 
L- Tryptophan 35.147  ✓ N/A 
L- Tyrosine 30.933 ✓  111 
 Urea 15.709  ✓ N/A 
 Uric acid 33.908  ✓ N/A 
L- Valine 14.956 ✓  5407 
3.7. Determination of limits of detection  
An important aspect in any analysis of a biological sample is the sensitivity of the assay, and how it relates to 
the concentration at which compounds of interest are present. A compound may be present in a biological 
sample but at a concentration below the detection limits for the type of instrument. In this project, the 
combined mixture was analysed using the final MS/MS method at 5 different concentrations of 423 ng/μL, 47 
ng/μL, 5.21 ng/μL, 572 pg/μL and 63 pg/μL to establish the lowest concentration at which each compound 
could be detected. A majority of the compounds (33) were still detected at the lowest concentration of 63pg/ 
μL. 11 of the compounds were only detected at 423 ng/μL, 18 of the compounds had a minimal detection limit 




of 47 ng/μL, 3 of the compounds had a minimal detection limit of 5.21 ng/μL, 4 compounds had a minimal 
detection limit of 572 pg/ μL and the remaining 12 compounds were not identified at any concentration. Table 
3.47 illustrates the upper and lower biological concentrations of the compounds in normal and Alzheimer’s 
CSF. The compounds shown in green demonstrate that the limit of detection is lower than any of the biological 
concentrations.  
 
Table 3.47: The upper and lower concentration ranges of the compounds classified by the Human Metabolome 
Database as being present in human cerebrospinal fluid, and their limits of detection which were established 
using the final MS/MS method on the Bruker SCION triple quadrupole GC-MS.  
 




















 Acetaminophen 2.570 0.756 N/A N/A 0.063 
Cis- Aconitic acid 4.701 0.054 N/A N/A 0.063 
 Adenine 0.027 0 N/A N/A 0.063 
 Adenosine 0.027 0.00035 N/A N/A 47 
 Adenosine Monophosphate 0.066 0 N/A N/A N/A 
 Adipic acid 0.31566 0.04676 N/A N/A 47 
B- Alanine 0.005 0 N/A N/A 47 
L- Alanine 6.504 0.320 N/A N/A N/A 
L-α- Aminobutyric acid 0.588 0.588 N/A N/A 47 
L- Arabinose 5.705 1.201 N/A N/A N/A 
L- Arginine 5051.800 1.484 1.289 0.801 0.063 
 Ascorbic acid 44.206 2.994 N/A N/A 47 
L- Asparagine 3.977 0 0.255 0.213 47 
 Azelaic acid 6.399 0 N/A N/A 0.063 
 Biotin 0.00021 0.00006 N/A N/A 423 
 Citric acid 121.036 21.133 N/A N/A 0.063 
 Cotinine 0.206 0 N/A N/A 423 
 Creatine 7.474 4.065 N/A N/A 0.063 
 Creatinine 10.452 3.507 N/A N/A 47 
3,4- Dihydroxybenzeneacetic acid 0.001 0.000013 0.00071 0.000086 0.063 
L- Dopa 0.00087 0.00051 N/A N/A 423 
 Dopamine 0.001 0 0.067 0.0000010 423 
 Epinephrine 0.011 0 N/A N/A 47 
 Ethanolamine 1.044 0.160 N/A N/A 0.063 
D- Fructose 46.842 12.431 N/A N/A 0.063 
 Fumaric acid 6.616 0.116 2.321 0.232 0.572 
 GABA 0.046 0 N/A N/A 5.21 
D- Galactose 47.742 12.071 N/A N/A 47 
D- Glucose 1268.326 281.050 756.672 576.512 0.063 
L- Glutamic acid 13.536 0 N/A N/A 0.063 
L- Glutamine 118.373 33.320 169.026 22.213 N/A 
 Glyceric acid 7.213 0 N/A N/A 423 
 Glycerol 4.881 1.013 N/A N/A 0.063 
 Glycine 1.426 0.225 0.030 0.012 N/A 
L- Histidine 4.375 0.931 N/A N/A 0.063 
 Homocysteine 3.028 0.003 2.150 0.008 423 
 Homovanillic  acid 0.200 0.000062 N/A N/A 47 
4- Hydroxy-L-Proline N/A N/A 0.044 0.029 0.063 
3- Hydroxybutyric acid 9.994 0 N/A N/A 47 
2- Hydroxyisobutyric acid 3.748 0 N/A N/A 423 
 Hypoxanthine 0.909 0.082 N/A N/A 423 
 Indoleacetic acid 0.072 0.00088 N/A N/A N/A 
 Inosine 0.322 0 N/A N/A 0.063 
Myo- Inositol 36.933 7.927 33.510 23.709 423 
 Isocitric acid 3.650 0.192 N/A N/A 0.063 
L- Isoleucine 2.387 0.118 0.400 0.230 0.063 




Table 3.47 continued : The upper and lower concentration ranges of the compounds classified by the Human 
Metabolome Database as being present in human cerebrospinal fluid, and their limits of detection which were 
established using the final MS/MS method on the Bruker SCION triple quadrupole GC-MS.  
 
2- Ketobutyric acid 0.633 0.347 N/A N/A 47 
 Kynurenic acid 0.015 0.00017 N/A N/A N/A 
L- Kynurenine 0.013 0.00035 N/A N/A 47 
L- Lactic acid 373.832 40.536 N/A N/A 0.063 
L- Leucine 3.279 0.918 1.705 1.312 47 
 Linoleic acid 3.926 2.244 N/A N/A N/A 
L- Lysine 6.140 2.339 8.099 4.941 0.572 
 Mannitol 1.330 0.510 1.221 0.820 47 
D- Mannose 12.972 1.982 N/A N/A 0.063 
L- Methionine 1.373 0.149 N/A N/A 0.063 
3- Methoxytyramine 0.00063 0.00020 N/A N/A 47 
 Methylmalonic acid 0.076 0.019 0.050 0.021 0.063 
 Nicotinic acid 2.168 0 N/A N/A 0.063 
 Norepinephrine 0.005 0.00001 N/A N/A 423 
 Oleic acid 20.337 0 N/A N/A 0.063 
 Oxoglutaric acid 1.797 0 N/A N/A 47 
L- Phenylalanine 4.625 0.330 1.123 0.859 0.063 
L- Proline 0.921 0 0.119 0.035 0.063 
 Putrescine 0.025 0.016 N/A N/A 5.21 
 Pyroglutamic acid 9.941 1.291 N/A N/A 0.063 
 Quinolinic acid 0.01671 0.00201 N/A N/A 0.063 
 Ribitol 5.417 0 0.682 0.475 5.21 
D- Ribose 0.751 0 N/A N/A 0.572 
 Scyllitol 1.441 0.360 N/A N/A 0.572 
L- Serine 6.305 0.728 N/A N/A 423 
 Sorbitol 4.569 1.729 4.846 3.561 0.063 
 Spermidine 0.023 0.012 N/A N/A N/A 
 Succinic acid 30.703 0.118 10.746 2.244 47 
L- Threonine 7.147 0.476 N/A N/A 0.063 
 Thymine 0.618 0 N/A N/A 47 
L- Tryptophan 5.841 0.184 0.331 0.200 N/A 
L- Tyrosine 6.052 0.544 5.794 4.055 0.063 
 Urea 458.858 0 N/A N/A N/A 
 Uric acid 7.851 0.706 N/A N/A N/A 
L- Valine 3.749 0.703 0.627 0.341 0.063 
 
3.8. Validation of the database  
To confirm that the method developed in this study could be used in the analysis of biological samples, 
cultured neurons and the media in which they were cultured were used as a substitute for CSF, which is very 
difficult to obtain. This approach allowed both intracellular and extracellular metabolites to be studied. 
Following analysis it was found that 36 of the 90 compounds included in this method were not identified in any 
of the sample types. Of the remaining 54 compounds, 37 were common to all sample types and 12 were 
common in the cells and conditioned media. Adenine and β-alanine were unique to the cell samples and 
glycine, hypoxanthine and scyllitol were unique to the clean media samples (Figure 3.23). It should be noted of 



























Figure 3.23: Graph representing the metabolites identified in cells (blue), clean media (red) and conditioned media (green) analysed using the final MS/MS method on the Bruker SCION triple quadrupole GC-MS. 




4. Discussion  
 
Alzheimer’s disease (AD) is a chronic neurodegenerative disease due to sustained atrophy of the brain, 
resulting in severe neurological dysfunction. It is the third most common cause of death in developed countries 
and the most common cause of dementia, accounting for 60-80% of all dementia cases in the developed world. 
(González-Domínguez, García-Barrera et al. 2012). Worldwide, approximately 36 million people suffer from this 
disease. In 2014, an estimated 5.2 million Americans have AD, and 5 million of these sufferers are aged 65 
years or older (Fargo and Bleiler 2014).  The advancement of medical technology is resulting in the population 
living longer, thus the number of AD cases is increasing (Fargo and Bleiler 2014). Studies have estimated that by 
2025 and 2050, the number of people aged 65 years or older with AD in the USA will increase to 7.1 million 
(40% increase) and 13.8 million respectively (Fargo and Bleiler 2014). This disease has a severe pathological 
impact on the patient, in addition to an emotional impact on their family. Furthermore, AD has a significant 
economic impact on the population. In 2013, Americans contributed 17.7 billion hours of unpaid caregiving to 
AD patients, with an estimated economic value of care of $220.2 billion/year (Fargo and Bleiler 2014). In 2014, 
Medicare and Medicaid are expected to pay $150 billion for health care, long-term care and hospices for 
people with AD and other dementias (Fargo and Bleiler 2014). For these reasons, it is fundamentally important 
that the cause of this disease is recognised to ultimately develop an appropriate treatment and decrease these 
statistics.  
 
In recent years, the identification of biomarkers in cerebrospinal fluid (CSF) has been a topic of considerable 
interest in AD research. It is proposed that CSF is the biofluid that best reflects any changes that occur in the 
brain. CSF has the most contact with the brain and is not separated by a regulated blood brain barrier. Any 
protein or metabolite changes in the brain should be reflected in the CSF, and any pathological changes would 
likely appear in the CSF before any other fluid (Anoop, Singh et al. 2010). It is believed proteins or metabolites 
could serve as biomarkers, and may be the biological entity that can act as a diagnostic tool and ultimately 
demonstrate the physiological pathways involved in the development of this disease. However, although 
considered a very informative fluid, attaining CSF is a highly invasive and painful process and this imposes 
restrictions due to limited supply (Anoop, Singh et al. 2010).  




Gas chromatography-mass spectrometry is now a widely used technique in metabolomic analysis. It has high 
chromatographic resolution and powerful capability to separate compounds within a mixture, and for this 
reason was the chosen technique for this project (Dunn, Bailey et al. 2005). Due to the limited supply of CSF, it 
is essential that as much data is captured from initial analysis to restrict the amount of CSF needed. To achieve 
this, an in-house GC-MS database was generated on the Bruker SCION triple quadrupole GC-MS. This database 
was built based on the metabolites that have so far be found in the CSF of healthy and AD patients, as classified 
by the Human Metabolome Database.  To generate this database, full scan, SIM/scan and product ion scan 
analyses were utilised in sequence to ultimately build a GC-MS/MS method that can be used to profile changes 
in CSF.  
4.1. Full scan analysis  
A full scan analysis is the simplest and initial GC-MS scan that can be performed. The purpose of this type of 
scan is to generate a total ion chromatogram of the sample, which displays the retention time against the 
relative abundance of an analyte (Grob and Barry 2004). The retention time is the time at which a compound 
elutes from the GC column, and is dependent on the chemical and physical properties of the compound. The 
lower the boiling point, the more volatile the compound, thus more time is spent in the mobile phase, allowing 
the compound to elute earlier and have a shorter retention time (McNair and Miller 2009). This time is not 
unique to a compound, and can be affected by alterations in the column length, internal diameter, film 
thickness and GC conditions. Variation in these conditions results in changes in the ratio between the 
stationary and mobile phases and thus in the distribution of the compound between the two phases (Smith 
1995).  Nevertheless, the retention time of a compound is a very useful qualitative measurement in GC-MS, as 
it constitutes the primary source of compound identification (Grob and Barry 2004).  
 
The chemistry of the column is a particular influence on the order in which compounds elute from that column. 
The polarity of the column will affect the length of time a compound spends in the stationary phase. A non-
polar column will cause non-polar compounds to interact more strongly with the column resulting in a longer 
retention time. Similarly on a polar column, a polar compound will have a greater interaction to the column 
and thus have a longer retention time (Herbert and Johnstone 2010). As stated in 1.6.1, compounds generally 




elute based on their volatility, however as stated above, the chemistry of the column will influence the elution 
pattern. A disadvantage in GC-MS is that compounds require derivatisation to manipulate volatility and stability 
(Dettmer, Aronov et al. 2007). Therefore the compounds being analysed are chemically different to their 
original form due to this chemical manipulation. Consequently, while the elution of compounds is still based on 
chemical properties, it is entirely dependent on the derivatisation process. For example, Figure 4.1 shows the 
normal structure of D-glucose, a very polar compound (Ruiz-Matute, Hernandez-Hernandez et al. 2011), and its 
derivatised structure. The chemical structure of glucose has changed, ultimately changing its properties. Notice 
the change in organisation of the compound and the addition of silyl groups. This manipulation increases the 









Figure 4.1: The derivatisation process of D-glucose. Step 1 illustrates the methoyxmation step. Step 2 illustrates the trimethylsilyation step. 
It should be noted this reaction uses BSTFA as opposed to MSTFA, which is what was used in this project, however the outcome is 
essentially the same. (Yi, Shi et al. 2014). 
 
Additionally, from this data it was found that some compounds exhibit multiple peaks and therefore retention 
times. This was due to isomerism and multiple derivative products being formed for the same compound. An 
isomer has the same molecular formula, but the chemical structure is different, which can affect its interaction 
with the stationary phase. Multiple derivative products occur as a compound can gain variable numbers of TMS 
groups, resulting in a change in the size of the compound, thus changing the retention time and fragmentation 
patterns for the compound (Dunn, Erban et al. 2013). Our data showed that one derivative or isomer was 
usually more reproducible than the other. The more reproducible feature was termed the parent metabolite 
and is probably so because it is more commonly formed (Dunn, Erban et al. 2013). The mechanism that results 
in one feature being more reproducible is currently unknown. 





The basis of this project was to identify the unique precursor-product ion pairs for each compound, in order to 
establish a database that could be used on a biological sample for confident and accurate identification. A 
precursor ion is generally the most abundant ion generated during fragmentation of the molecular ion, and 
further dissociation of the precursor ion results in the generation of product ions (Watson and Sparkman 
2008). The fragmentation pattern is proportional to the manner in which an ionised molecule fragments. The 
molecular structure, spatial arrangement, ionisation potential and internal energy all reflect the way a 
particular compound will fragment (Stashenko and Martínez 2012). When a compound is initially introduced to 
the mass spectrometer, a beam of 70 eV electrons collides with the compound, resulting in the removal of an 
electron and absorption of energy forming a molecular ion (M
+
) (Skoog, Holler et al. 2007, Stashenko and 
Martínez 2012). During this process, a collection of molecular ions with a distribution of energies is generated. 
The greater the amount of energy absorbed, the greater the ability of the ion to fragment (Watson and 
Sparkman 2008). The signal intensity is related to the ability of the ion to delocalise its positive charge so that 
fragmentation is unable to occur. Thus, the stability of an ion will determine the nature of fragmentation 
(Stashenko and Martínez 2012).  
 
For example, Figure 3.7 shows the mass spectrum of the 2-TMS derivative of L-proline, showing that m/z 142 
was the most favoured fragmentation product; the small number of fragmentation products suggests that the 
precursor ion was extremely stable. Figure 3.8 illustrates a mass spectrum of the TMS derivative of thymine, 
the greater number of fragmentation products suggests that this compound fragments more readily. From the 
mass spectrum, it is reasonable to suggest that this compound can fragment because it can be ionised at 
multiple sites. As can be seen, the most abundant unique ion, or base peak, was m/z 255, but m/z 270 also had 
a relatively high intensity, and could not be a product of base peak fragmentation. Additionally, there were 
multiple fragmentation products with a m/z less than 255, suggesting that this ion was relatively unstable and 
further fragmented. 
 
Using the mass spectrum, which contains the fragmentation pattern of the compound, SIM ions were selected 
based on the following criteria: the signal of each ion should be above 30% relative intensity, the mass-to-
charge (m/z) ratio of the ions should be greater than 100; the ions should not coincide with background signals 




(17, 18, 28, 32, 40, 43, 44) and thermal degradation products (149); and, where avoidable, m/z 73 and 147 ions 
should not be selected (Fernandez-Alba 2004, Stashenko and Martínez 2012). These specifications were 
implemented for several reasons. The signal of an ion demonstrates its stability; the higher the intensity, the 
greater the stability. Choosing an ion that has a relative intensity that is below 30% increases the risk that this 
ion will not always form during fragmentation, and is therefore not ideal for compound identification. It is 
preferred that the chosen ions have a m/z greater than 100, because the lower the m/z, the more likely an ion 
will be shared by two or more compounds. Larger m/z values are more likely to be unique to a specific 
compound (Stashenko and Martínez 2012). Background signals and degradation products should not be 
chosen, as they are not unique to any compound. Furthermore, m/z 73 was present in almost every spectrum, 
and on some occasions was the base peak, because this ion is a result of the fragmentation of one of the silyl 
groups used during derivatisation. Similarly, m/z 147 was present in many mass spectra as it represents the 
fragmentation of two silyl groups (Watson and Sparkman 2008). 
 
For most compounds only three ions were selected, with the most abundant ion termed the base peak or 
quantifier ion of a compound. The base peak generally has a relative intensity of 100% and is considered the 
most stable ion (Hoffmann and Stroobant 2007). The next 2-3 most abundant ions were chosen as qualifier 
ions and were displayed on the mass spectrum relative to the base peak value. For some compounds, the 
selection of four ions was possible, probably due to the chemical structure of those compounds. When these 
compounds become ionised, their ability to delocalise the positive charge may be lower, resulting in greater 
fragmentation (Stashenko and Martínez 2012). 
 
It was established that multiple compounds could not be identified from the full scan analysis, and there are 
many possible reasons for this. Existing GC-MS data (retention time, retention index or base peak) was not 
available for many of these compounds, making identification difficult, and the lack of prior GC-MS data does 
suggest that these compounds are possibly unable to be detected on a GC-MS instrument. The unidentified 
compounds may not be GC-amendable due to their molecular size after derivatisation, or due to other 
chemical and physical properties (Grob and Barry 2004). There are alternative techniques that can be used to 
verify whether compounds are GC-amendable. For example, the GC method can be altered or different 
columns can be used to account for the physical and chemical properties. Compounds may also have been lost 




in sample preparation, due to an inability to survive the freeze-drying process. The loss of metabolites during 
the freeze drying process is inevitable, as some compounds are labile and ultimately degrade (Smart, Aggio et 
al. 2010). Although there is no direct evidence, it is reasonable to suggest that reaction between two 
compounds could result in the loss of one or both compounds. The non-identified compounds could be 
analysed in isolation to establish if the compound cross-reacted with other compounds included in the mixture.  
4.2. SIM/scan analysis 
Selected ion monitoring or SIM/scan analysis was completed after the identification of the quantifier and 
qualifier ions from full scan analysis. This scan was used to increase the signal/noise (S/N) ratio, by decreasing 
background signals (Wells and Huston 1995). In this scan mode, the mass analyser was set to scan for specific 
m/z ions for each compound, decreasing the amount of unwanted m/z values being detected. This technique 
therefore increased the sensitivity and reproducibility of a compound by acquiring more data per unit time 
(Wells and Huston 1995, Tsugawa, Tsujimoto et al. 2014).   
 
As previously stated, when choosing SIM ions there are particular factors to be considered. The key criterion 
suggested for SIM ions is a relative intensity above 30%, although for some compounds, the intensity of all or 
some of the ions generated was below this range, and therefore it was inevitable that they were chosen as the 
SIM ions. The signal intensity is proportional to the abundance of the ion, and thus if the signal is low, the 
abundance of the ion is low (Stashenko and Martínez 2012). From our data it was observed that not all ions 
chosen from the full scan were reproduced in the SIM/scan, most likely because some compounds had poor 
fragmentation or the ions chosen were below 30% relative intensity. The likelihood of this ion appearing in 
every mass spectrum was low because its initial low abundance indicates instability (Stashenko and Martínez 
2012).  
 
For example, Figure 3.10 shows the ion chromatograms of the TMS derivative of ribitol. The reproducibility of 
the three SIM ions, m/z 217, 205 and 103, suggests that these ions were the common fragmentation products 
of this compound. Thus, they would be reliable ions to use as precursors for the MRM scan. Figure 3.11 
displays the ion chromatograms of the TMS derivative of adipic acid. These chromatograms suggest that the 




three SIM ions m/z 111, 141 and 83 were the common fragment ions of this compound. Furthermore, it 
appears the m/z 275 ion was not a common fragment ion. The intensity of this ion was below 30%, which could 
be why it did not appear in this SIM/scan analysis. Although the m/z 111, 141 and 83 ions did have intensities 
above 30%, the m/z 275 ion was chosen because m/z 83 was smaller than the m/z 100 cut-off. The m/z 275 ion 
was chosen to investigate whether it could be used as a precursor ion in spite of its low intensity. Figure 3.12 
illustrates the ion chromatograms of the TMS derivative hypoxanthine. From these chromatograms, it is 
reasonable to imply that this compound was easily fragmented when ionised. The stability of these ions may be 
low, leading to further fragmentation.  The intensity of the m/z 265, 280 and 266 ions was initially below 30%, 
however they were chosen as SIM ions because they were the most abundant in the spectrum. Although a SIM 
scan is useful as it increases sensitivity for a compound, the possibility still exists that the selected ion will 
match a background signal, which lowers the reliability of the SIM method. To overcome this, a multiple 
reaction monitoring (MRM) scan is used to monitor precursor-product ion pairs.  
4.3. Product ion scan analysis 
The SIM/scan was used to clarify the most abundant ions produced during fragmentation of a compound. The 
ions that were reproduced in the SIM scan were selected as precursor ions in the product ion scan. In this scan, 
Q1 filters the selected precursor ions, they then pass through to Q2 where they collide with argon, causing 
further dissociation. Finally, Q3 scans for the product ions that are produced from the dissociation of the 
precursor ions (Skoog, Holler et al. 2007). 
 
Similar to the SIM data, not all precursor ions were reproducible; likely for the same reasons discussed above. 
The relative intensity of some of these ions may have been below 30% in the full scan analysis, however, they 
were chosen for SIM due to limitation on the number of fragments. Although the relative intensity was below 
30%, the fragmentation pattern may have coincidentally been the same in the SIM/scan, resulting in sufficient 
reproducibility. However, in the precursor scan, the same fragmentation pattern may not have been produced. 
This inconsistency in the data demonstrates why it is important to choose ions with a relative intensity greater 
than 30%. For the ions that were sufficiently reproducible, the signal/noise ratio increased with product ion 




scan. This was due to a further decrease in the background noise, resulting in an increase in the signal/noise of 
the compound (Chernushevich, Loboda et al. 2001). 
 
The product ions produced depend on the dissociation of the precursor ions. When the precursor ion collides 
with the argon gas in Q2, the collision provides the precursor with energy and causes the ions to convert part 
of their kinetic energy into internal energy (Watson and Sparkman 2008). The amount of energy available 
influences the dissociation of the ion.  Furthermore, the charged state of the ion impacts the nature of 
dissociation. The reason for this is because an ion gains energy from an electric field in proportion to the 
number of charges it carries. Thus, the more charges the ion has, the more energy it will absorb, resulting in 
greater dissociation. For this reason, the collision energy must be optimised to ensure sufficient dissociation 
(Watson and Sparkman 2008). 
 
This is evident in this data, as there was a variation of the optimised collision energy for each precursor, 
demonstrating that each ion requires optimisation to find the correct level of energy for dissociation. For 
example, Figure 3.14 illustrates the mass spectrum of the m/z 368 precursor ion of the TMS derivative of L-
DOPA, showing the dissociation pattern of this ion using 5 V collision energy. The m/z 368 precursor ion readily 
dissociated when hit with a low energy, suggesting that this ion does not carry many charges. Similarly, Figure 
3.16 shows the mass spectrum of m/z 136 precursor ion of the TMS derivative of nicotinic acid at 15 V collision 
energy. For dissociation, this ion required more energy than the m/z 368 ion of L-DOPA, possibly because the 
m/z 136 ion has more charges. Figure 3.18 displays the mass spectrum of the m/z 154 precursor ion of the TMS 
derivative of L-histidine at 35 V collision energy. This mass spectrum shows poor dissociation, even at the 
optimal energy for this precursor. This suggests the ion may be fairly stable and does not readily dissociate.   
 
When deciding which precursor-product ion pairs to use in the MRM scan, it is recommended to choose the 
most abundant product ion and, if possible, larger m/z product ions. The more abundant the ion, the more 
stable it is, and therefore is a reproducible fragment for that compound. Furthermore, the higher the m/z of 
the product ion, the more unique it is to that compound, providing more accurate compound identification 
(Chen 2013).  




4.4. MRM scan analysis 
The product ion scan was used to identify the precursor-product ion pairs of a compound, which was then 
analysed using the multiple reaction monitoring (MRM) scan. The basis of this scan is to establish the most 
abundant and optimal precursor-product ion pairs for each compound. This scan further increases the 
signal/noise ratio, because the precursor ions that pass through Q1 and product ions that pass through Q3 are 
selected for. For this reason, the probability of the analyte ions coinciding with a background signal is almost 
completely lost, thus increasing the signal/noise ratio (Stashenko and Martínez 2012). A maximum of 5 
transitions were chosen to ensure that the occurrence of an analyte could be confirmed with 100% confidence.  
 
Figures 3.19 and 3.20 illustrate overlaid ion chromatograms of 10 transitions of the TMS derivative of nicotinic 
acid and five transitions of the TMS derivative of azelaic acid, respectively. Based on these chromatograms, it is 
reasonable to suggest that these compounds were highly reproducible using this GC-MS technique. The 
fragmentation and dissociation of each compound was adequate to give highly reproducible precursor and 
product ions, but the ions were also sufficiently stable to ensure complete fragmentation did not occur, so the 
compounds remained identifiable. Figure 3.21 displays an overlaid ion chromatogram of five transitions of the 
TMS derivative of urea. From this ion chromatogram, it is reasonable to suggest that GC-MS was not an ideal 
technique to identify this compound. The fragmentation of this compound was highly inconsistent, resulting in 
insufficient unique ions that could be used as transitions to identify this compound in a biological sample. A 
reason for this could be due to instability of the precursor ion. 
4.5. Method optimisation  
Optimisation is an important aspect when developing a method, to assure that the best possible data is 
achieved with the final MS/MS method. There are many different approaches that can be used for the 
preparation of metabolomics samples, and for this reason optimisation is required to identify any factors that 
may affect compound identification. Following method optimisation, it was found that there are many factors 
which could alter the data and potentially limit the applicability of this method.  
 




Although GC-MS has the ability to identify a large number of compounds in a complex mixture, there are 
limitations. A common problem that occurs in GC-MS is the confusion of artefacts with analytes, which can 
result in false identification of compounds. An artefact is an entity that is identified by the analytical technique, 
but is not part of the sample. Artefacts are errors, generally from the instrument or the equipment used in the 
preparation of the samples. Some common examples of artefacts include: vacuum pump oil, which has 
substantial vapour pressure and can thus bleed into the ion source; phthalates, which are commonly used to 
stabilise the plastic or rubber seals in the instrument; plastic in tubes and bottles that store standards; air; and 
water (Grob and Barry 2004). These examples are some of many entities that can cause the appearance of 
erroneous peaks in the data.  
 
Contamination is also an issue that can result in inconsistent data. From this data, it appears that minimal 
contamination occurred. In mixtures 4, 5 and 6, homocysteine was identified. Homocysteine was included in 
mixture 3, and thus the reason for its appearance in subsequent mixtures could be carry-over. Sample carry-
over occurs when a compound from a previous sample is identified in a subsequent sample, which could be 
due to the GC injector and/or column retaining residual compound. To reduce the chance of sample carry-over 
a blank injection can be included after each sample to clean the injector and column (Fialkov, Steiner et al. 
2007).  Another example of carry-over may be the appearance of sorbitol in mixtures 1, 5 and 6, as sorbitol was 
initially included in mixture 4. Identification in mixture 1 could be contamination of sorbitol in the mixture, or 
the misinterpretation of the compound due to another compound in mixture 1 which has a similar retention 
time and fragmentation pattern to sorbitol. This however is a common problem with sugars and sugar alcohols, 
because these compound classes generally have similar chemical structure. For this reason the fragmentation 
pattern can almost be identical inflicting challenges in compound identification between these classes of 
compounds (Bhagavan 2002).  
 
Another problem that may be encountered when dealing with complex mixtures is the chance that a 
compound will not be identified due to cross-reaction. As described in section 4.1 the theory that 2 compounds 
react can be a reason for the complete loss of a compound. When this occurs, the compound will not be 
identified during GC-MS analysis, which can cause problems when studying biological samples. The MS/MS 
method developed in this project was based on six mixtures of approximately 10-20 compounds and although 




this technique is useful, it is not representative of a biological sample, which may contain compounds that 
cross-react or co-elute. In order to represent these physiological conditions, a large mixture containing all the 
identifiable compounds in this project was produced.  It was found that multiple compounds were lost when 
combined. This is a potential limitation to studying disease processes, as particular metabolites may be 
involved in the pathological process, however may be unable to be identified due to cross-reaction.  
4.6. Limits of detection 
The limit of detection determines the lowest analyte concentration that still produces a measurable response 
(Goldberger, Huestis et al. 1997). According to the Human Metabolome Database, the concentration of a 
compound varies in a biological sample, whether it be in a healthy or normal state (available at: 
http://www.hmdb.ca/). It is important to recognise the lowest concentration at which a particular compound 
will be detected on a particular instrument to ensure the best data is generated. Some compounds have lower 
sensitivity on GC-MS and can be better detected on another analytical platform; whereas other compounds are 
highly reproducible on GC-MS and can be detected at extremely low concentrations. If a compound were 
unable to be detected at the concentration at which the compound is present in biological samples, further 
analysis would be required to identify all compounds within a sample. As stated in section 1.6, no one 
instrument has the capability to identify all classes of compounds with both reproducibility and sensitivity, 
therefore it is standard procedure that multiple techniques are required to completely profile the compounds 
present in a biological sample (Dunn, Bailey et al. 2005). In this project, it was found that multiple compounds 
used to build this database have a detection limit lower than the biological concentration, thus this method 
would be able to detect the compounds in CSF samples. However, some compounds have a lower biological 
concentrations than could be identified by this instrument. It should be noted that the HMDb provides a range 
rather than an exact concentration, therefore for some compounds in this study, the lowest detection limit is 
within this range, but it may not be able to detect the minimal biological concentration. In future studies, the 
mixture should be further diluted to determine the limit of detection for compounds that remained detectable 
at the lowest concentration used in the current study.  




4.7. Validation of the database 
To ensure that the method developed in this study could be used in the analysis of biological samples, cultured 
neurons, the media in which they were cultured, and fresh media were analysed, as a substitute for CSF, which 
is difficult to obtain.  From this data, it was found that a total of 54 metabolites included in this method were 
analysed across the three samples types. Of these 54 compounds, 37 were common to all sample types, and 12 
were common between cells and conditioned media. Adenine and β-alanine were unique to the cell samples 
and glycine, hypoxanthine and scyllitol were unique to the clean media samples. The 37 common metabolites 
consisted of the 15 amino acids, including both L-proline derivatives, and 5 sugars, including both glucose and 
fructose isomers and D-ribose. These metabolites are essential for cell survival; therefore it was expected to 
find these metabolites in both extracellular and intracellular samples.  
 
In the clean media, a total of 40 metabolites were identified. 16 of these metabolites, including glycine (one of 
the metabolites unique to the clean media) were included in the proprietary formulation of the media. As 
stated in section 2.6.1, this media also contains foetal calf serum, suggesting that the remaining metabolites 
came from this source. Ideally, all metabolites identified in clean media would also be identified in the 
conditioned media, however this did not occur. Glycine, hypoxanthine and scyllitol were identified in the clean 
media but not the conditioned media, suggesting the cells may have utilised these metabolites for growth, 
reducing their levels below the limits of detection.  
 
In the cells, a total of 39 intracellular metabolites were identified, of which 37 were also found in the other two 
sample types. As previously stated, of these 37, it was found that 15 were amino acids and 5 were sugars, 
which is expected as amino acids and sugars are essential for cell survival. Therefore it is not abnormal that 
these metabolites were also found in the clean media, either from the initial ingredients or from the foetal calf 
serum. The remaining common compounds suggest that the cells absorbed metabolites from foetal calf serum. 
The extracellular and intracellular metabolites were almost identical, suggesting that the cells excreted a 
majority of their metabolites into their surroundings. The only difference was adenine and β-alanine, which are 
essential metabolites for cell division, and therefore it is likely the cell was utilising these metabolites.  The 12 




metabolites that were unique to the cells and conditioned media are noteworthy. The difference between the 
clean media and the cells and conditioned media is the basis of pathway identification.  
4.8. Limitations and future directions 
Although GC-MS has high chromatographic resolution and the ability to separate compounds within a complex 
mixture, there were limitations in this project. Some of these limitations can be accounted for and a number of 
alternative steps could be taken as this project continues.  
 
A major limitation in this project was the inability to identify some of the compounds in the full scan analysis. 
This could be a result of compound loss during sample preparation or unsuitable GC conditions.  During sample 
preparation, it is possible that some compounds cross-reacted, resulting in the complete loss of one or both of 
the compounds. To overcome this limitation, alternative steps can be considered. To establish if compounds 
cross-react, the unidentified compound(s) can be analysed in isolation. Additionally, in the freeze-drying 
process some compounds are labile and ultimately degrade which is an important limitation as freeze-drying is 
a critical step in GC-MS, and thus degradation may be inevitable (Smart, Aggio et al. 2010). Furthermore, 
sample preparation was not fully optimised for the validation samples, meaning that some compounds may 
have been lost in this process. In future, method optimisation should be considered to ultimately yield the best 
possible data. In addition to optimisation, alternative sample preparation methods should be considered to 
establish whether another method such as solid phase extraction will result in more reproducible data.  
 
Another possible reason for unidentified compounds in the full scan analysis could be chromatography. Co-
elution is one possibility that would result in the inability to identify a compound. To overcome this limitation, 
these compounds can be analysed in isolation to determine whether co-elution occurred. Additionally, the GC 
method and/or the column could be altered to adjust for the chemical and physical properties of the 
compounds under analysis. Furthermore, as previously stated, another possible reason for compound loss 
could be due to increased molecular size due to derivatisation. To account for this factor, analysis can be 
performed using LC-MS as derivatisation is not needed for this technique. Another consideration is the small 




amount of carry-over, or cross-contamination, that occurred. If these analyses were to be repeated, a blank 
sample should be run after each sample to reduce interference from contamination.   
 
Finally, limitations occurred at the MS stage. While the data generated was robust, analyses could be repeated 
to further optimise the data collection. When determining the product ions generated from a precursor ion, 
the optimal collision energies were estimated rather than accurate. To determine the exact optimal collision 
energy, each precursor should be analysed using a consecutive range of energies to conclude the exact energy 
which provides the best results. For example, the optimal energy for the m/z 368 product of the TMS derivative 
of L-DOPA was 5 V, however the other energies tested were limited to 15, 25, 35 and 45 V. To establish the 
exact optimal collision energy, this precursor should be analysed using 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 V collision 
energies.  
 
The next steps in this project would be to further advance the database to ultimately build a MS/MS method 
that contains transitions for all the metabolites that have so far been identified in CSF. This fully developed 
database could then be used to profile CSF and establish the biochemical changes that occur as a patient 
progresses from a healthy state to mild cognitive impairment, and finally to Alzheimer’s disease. It should also 
be considered to use another technique such as LC-MS in addition to GC-MS. As stated above not one 
instrument has the ability to detect every metabolite. Therefore using two different techniques would broaden 
metabolite identification. Another future direction would be advancing the database using compounds that 
have not been identified in CSF. Limiting the analysis purely to compounds that have already been identified in 
CSF does raise the possibility of missing important unknown metabolites. This opens up avenues to detect new 
CSF metabolites, which may be important to the development of Alzheimer’s disease.   
 
Studying the changes in metabolites of Alzheimer’s patients will ultimately establish the pathways that are 
involved in the development and progression of the disease. Furthermore this database can also be used to 
profile changes in other neurodegenerative diseases. As classified by the human metabolome database 
(available at: http://www.hmdb.ca/), there are multiple metabolites that are consistent among several 
neurodegenerative diseases, such as Parkinson’s disease and Huntington’s disease. Thus this method will not 
only impact Alzheimer’s research but could potentially assist in the research of other diseases. 





The aim of this project was to generate a mass spectral database using full scan, selection ion monitoring (SIM) 
scan and multiple reaction monitoring (MRM) scan analysis on the Bruker SCION triple quadrupole GC-MS that 
could be used to profile changes in CSF, and to validate this database using appropriate samples. In this project 
a total of 90 CSF features (81 compounds) were identified and ultimately built into a database. A key outcome 
of this database construction was the identification of optimal precursor-product ion pairs for these 
compounds. Initially, the most abundant fragment ions were identified for each compound and analysed to 
establish the precursor ions. Once known, these precursor ions were analysed in isolation to establish their 
product ions following dissociation. Up to 5 of the optimal precursor-product ion pairs were selected for each 
compound and built into the final MS/MS method. The purpose of identifying these precursor-product ion pairs 
was to create the database where each compound has a unique set of transitions, such that when used on a 
biological sample, a compound can be identified with accuracy and confidence.  
 
 
The database was validated using neuronal cells, the media in which they were cultured and clean media as a 
control. The validation process was used to confirm that this database has a potential use in profiling biological 
samples. This was evident by the identification of 54 metabolites analysed across the three sample types, 
where 37 of these were common amongst all three sample types. 12 of these were unique to the neuronal cells 
and conditioned media. Two metabolites were unique to the neuronal cells and three were unique to the clean 
media. Therefore this MS/MS database could be used to investigate the changes that occur between healthy 
and Alzheimer’s CSF to recognise the significant metabolite changes that occur.  These metabolites could serve 
as potential biomarkers that can be used as diagnostic tools and to monitor disease progression.  However the 
most important use of these metabolites is to establish the initial cause of this disease by identifying the 
biochemical pathways which are involved in the pathological changes that occur.  Once identification is 
achieved, an appropriate treatment can be developed to target these pathways. To achieve the aim of 
understanding the biological pathways that are involved in this disease, a database such as this is required, 
which is hopefully a first step in a better understanding of this disease.  
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Table 6.1: The transitions and their collision energies chosen for mixture 1 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 
          Compound 





Collision energy (V) 
 






























L- Arabinose 25.965 



























Table 6.1 continued: The transitions and their collision energies chosen for  mixture 1 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 























133 115 15 




















4- Hydroxy-L-Proline 22.85 












Table 6.1 continued: The transitions and their collision energies chosen for  mixture 1 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 
































3- Hydroxybutyric acid 13.181 117 75 35 







4- Hydroxy-L-Proline 22.85 





















Table 6.1 continued: The transitions and their collision energies chosen for  mixture 1 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 


























2- Ketobutyric acid 11.351 





























Table 6.1 continued: The transitions and their collision energies chosen for  mixture 1 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 
    214  
L- Kynurenine 35.230 







L- Kynurenine 34.723 
218 192 5 





























































































Table 6.2: The transitions and their collision energies chosen for mixture 2 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 
          Compound 





Collision energy (V) 
 Azelaic acid 28.194 























175 73 15 





86 75 5 





D- Fructose 30.253 217 128 5 
D- Galactose 30.414 319 217 5 















160 105 5 












Table 6.2 continued: The transitions and their collision energies chosen for mixture 2 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 








204 189 5 
L- Glutamine 27.923 
128 75 25 












191 73 15 
217 73 15 
L- Lactic acid 10.008 
































































174 86 15 
D- 
Ribose 26.307 
103 91 5 











191 73 15 
217 73 15 
L- 
Valine 14.956 





















Table 6.3: The transitions and their collision energies chosen for mixture 3 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 
Compound 





Collision energy (V) 








 Ascorbic acid 29.450 












L- Glutamic acid 22.699 




















 Homocystine 25.723 
128 73 15 


















Table 6.3 continued: The transitions and their collision energies chosen for mixture 3 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS 
 




159 74 15 
158 73 15 























217 129 5 









 Thymine 19.924 































130 103 25 
L- Tyrosine 30.933 
179 73 15 
218 100 5 





130 97 15 
 110  
 115  
 
































Table 6.4: The transitions and their collision energies chosen for mixture 4 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 





Collision energy (V) 
L- Alanine 11.310 
190 149 15 




L- Asparagine 22.180 













189 149 15 
 Epinephrine 31.466 














160 73 15 
D- Glucose 30.825 












L- Methionine 22.628 
128 73 15 
176 128 15 













Table 6.4 continued: The transitions and their collision energies chosen for mixture 4 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 




L- Proline 17.159 142 73 15 

















156 73 15 
 Ribitol 27.222 
217 129 15 






 Sorbitol 31.199 












 Succinic acid 17.611 
















Table 6.5: The transitions and their collision energies chosen for mixture 5 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 





Collision energy (V) 
















 Adipic acid 22.261 
111 83 15 
141 75 15 
83 55 15 
L- Arginine 28.858 

























174 86 15 

















Table 6.5 continued: The transitions and their collision energies chosen for mixture 5 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 
    319  
 







































Table 6.6: The transitions and their collision energies chosen for mixture 6 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole GC-MS. 
 
 
             Compound 
 





Collision energy (V) 
L-α- Aminobutyric  acid 13.633 
204 149 15 
130 73 15 
131 74 15 

















































Table 6.6 continued: The transitions and their collision energies chosen for mixture 6 compounds to be analysed using a MRM scan analysis on the Bruker SCION triple quadrupole 
GC-MS. 
 
L- Histidine 30.655 154 73 35 





100 70 25 




129 75 15 
117 75 35 
 Oxoglutaric acid 23.956 












144 128 35 
116 
112 5 
89 35 
 
 
 
 
 
 
 
 
 
